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December 2018
Cancer is the second driving reasons for death around the world. It is an abnormal
growth of cells which can migrate and recreate cellular microenvironment and can also
be caused by successive alterations that occur in a set of specific genes in the cell. As
dangerous and deadly as cancer is, there is still a gap in our understanding of the mech-
anism of its establishment, its recurrence cycle and its elimination. It was observed that
cancer stem cells are regulated by the complex interaction component that makes up the
tumor microenvironment (TME), through a network of growth factors and cytokines.
Therefore, focusing on and understanding the role of these components and the level
of concentration of modulating factors present in the TME can play a significant role in
battling cancer. Many research projects have investigated the dynamics of these cy-
tokines in the context of cancer in order to understand the evolution of cancer for im-
proving diagnostic, prognostic and therapeutic strategies. However, these research are
mostly restricted to cells that directly perform cytotoxic effect on cancer cells, such as the
natural killer (NK) and cytotoxic T lymphocytes (CTLs or CD8 + T) cells. They do not
explicitly integrate cytokine-mediated innate-adaptive immunity in the tumor dynam-
ics. Moreover, none of those research has combined cellular-level mathematical models
with protein-protein interaction network analysis, to predict essential proteins, biologi-
cal processes and enriched pathways associated with cancer disease.
ii
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Hence, in this study, we present a new mathematical model to investigate the dy-
namics between tumor cell and host immune system component (i.e., innate and adap-
tive immune cells and cytokines) in the TME . Results from the numerical solution of our
model indicate the capacity of a tumor to escape from immunologic surveillance due to
low cytotoxic immune cells (i.e. NK cells and CD8 + T cells) at the tumor site while
more of these cytotoxic immune cells at the tumor site results in tumor regression. Our
model, therefore, supports strengthening the cytotoxic immune cells in the TME which
we see as a significant way of contributing to tumor regression. Also, from the analysis
of our model, cytokines such as IL-10, IL-23, TNF-α, TGB-β and IFN-γ has been shown
to make contributions significantly to the dynamics of tumor development based on the
observed dynamics in the level of concentrations in the TME.
Finally, switching of an immune (effector) cell from resting to active states, is trig-
gered by some proteins working in a complex protein-protein interaction (PPI) network.
We identified proteins which likely regulate immune cells and cytokines contributing to
breast cancer disease outcome and infer essential proteins based on Protein-proteins
interaction network, as well as significant pathways and enriched biological processes
associated with breast cancer. These biological processes and pathways and essential
proteins identified can be further assessed to check for their suitability as targets for the
breast cancer disease for the improvement of effective therapeutic strategies.
Keywords: Immune cells, Tumor cells, Cytokines, TME, Mathematical modelling, Pro-
teins.
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Opsomming
Stelsel Vlak Kanker Siektes Teiken Identifikasie met behulp van Tumor
Mikro Omgewing Dinamika
(Systems Level Cancer Disease Target Identification Using Tumor Microenvironment Dynamics )
Funmilayo Lydia MAKINDE
Departement Wiskundige Wetenskappe,
Universiteit van Stellenbosch,
Privaatsak X1, Matieland 7602, Suid Afrika.
Tesis: MSc. (Wiskunde)
Desember 2018
Kanker is die tweede oorsaak van dood ter wêreld. Dit is ’n abnormale groei van selle
wat kan migreer en herskep sellulêre mikro-omgewing en kan ook veroorsaak word
deur opeenvolgende veranderinge wat voorkom in ’n stel spesifieke gene in die sel.
So gevaarlik en dodelik soos kanker vir ons samelewing is, is daar steeds ’n gaping in
ons begrip van die meganisme van sy vestiging, sy herhalingsiklus en die uitskakeling
daarvan. Dit is opgemerk uit navorsing dat kanker stamselle gereguleer word deur die
komplekse interaksie komponent wat die tumor mikro-omgewing (TME), deur middel
van ’n netwerk van groeifaktore en sitokiene.
Daarom fokus op en verstaan die rol van hierdie komponente en die vlak van kon-
sentrasie van moduleringfaktore wat in die TME teenwoordig is, kan ’n belangrike rol
speel in die stryd teen kanker. Baie navorsingsprojekte het die dinamika van hierdie si-
tokiene ondersoek in die konteks van kanker om die evolusie van kanker te verstaan vir
die verbetering van diagnostiese, prognostiese en terapeutiese strategieë. Hierdie na-
vorsing word egter meestal beperk tot selle wat direk sitotoksiese effek op kankerselle,
soos die natuurlike moordenaar (NK) en sitotoksiese T limfosiete (CTLs of CD8 + T)
selle. Hulle integreer eksplisiet sitokien-gemedieerde aangebore-adaptiewe immuniteit
in die tumor dinamika. Daarbenewens het geen van hierdie navorsing op wiskundige
iv
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modelle op sellulêre vlak met proteïen interaksie netwerk analise ondersoek om noods-
aaklike proteïene, biologiese prosesse en verrykde paaie wat met kanker geassosieer
word te voorspel nie.
Daarom bied ons in hierdie studie ’n nuwe wiskundige model wat saamgestel is uit
gewone differensiaalvergelykings om die dinamika tussen tumorselle en gasheer im-
muunstelsel komponent (dws aangebore en adaptiewe immuunselle en sitokiene) in
die TME. Resultate van die numeriese oplossing van ons model dui aan die kapasiteit
van ’n tumor om te ontsnap uit immunologiese toesig is as gevolg van lae sitotoksiese
immuun selle (dws NK-selle en CD8 + T selle) by die tumor terwyl meer van hierdie
sitotoksiese immuun selle op die tumor site in tumor lei regressie. Ons model onder-
steun dus die versterking van die sitotoksiese immuun selle in die TME wat dien as ’n
duidelike manier om by te dra tot tumorregressie. Ook, uit die analise van ons model,
sitokiene soos IL-10, IL-23, TNF-α, TGB-β en IFN-γ is getoon dat dit ’n bydrae lewer tot
die dinamika van die tumor ontwikkeling gebaseer op die waargenome dinamika in die
vlak van konsentrasies in die tumor mikro-omgewing.
Laastens, die omskakeling van ’n immuun (effektor) sel van rus na aktiewe toe-
stande word gereguleer deur sommige proteïenwerk in ’n komplekse proteïen-proteïen
interaksie (PPI) netwerk. Ons het proteïene geïdentifiseer wat waarskynlik immuun
selle en sitokiene reguleer wat bydra tot die uitkoms van borskanker siektes en essensi-
ële proteïene gebaseer op proteïen-proteïen interaksie netwerk, asook belangrike paaie
en verrykde biologiese prosesse wat met borskanker geassosieer word, aflei. Hierdie
biologiese prosesse en paaie en noodsaaklik proteïene geïdentifiseer kan verder geas-
sesseer word om na te gaan of hulle geskik is vir teikens vir die borskanker siekte vir
die verbetering van effektiewe terapeutiese strategieë.
Keywords: Immuun selle, Tumor selle, sitokiene, TME, wiskundige modellering, prote-
ïene.
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Chapter 1
Introduction
1.1 Background
1.1.1 Evolution of cancer in the tumor microenvironment (TME)
Cancer can be characterized as a group of disease formed as a result of uncontrolled
development and spread of abnormal cells which occurs in different parts of the body
or organs. According to the World Health Organisation (WHO), cancer is the second
driving reason for morbidity and mortality [116]. As shown in Figure 1.1, about 16% of
people died from cancer in 2016. Likewise, 30% of most cancer deaths are due to the
five leading behavioural and dietary risks, namely: high body mass index, low fruit and
vegetable intake, lack of physical activity, alcohol use and tobacco use. Tobacco use is
the most salient risk factor for cancer. It causes 22% of global cancer mortalities and 71%
of global lung cancer mortalities [115]. Cancer can also be caused by viral infections
such as hepatitis B virus (HBV), hepatitis C virus (HCV) and human papillomavirus
(HPV). They have been seen to cause up to 70% of all cancer deaths in low- and middle-
income countries in 2008 [115]. Furthermore, there are some non-modifiable risk factors
which cause cancer, of which are, inherited genetic mutation, hormones and immune
conditions [16]. It has been observed that some types of cancer are more common in
men and women. The five most common types of cancer recognised in 2012 affecting
men are: lung (with 16.7% of the total death), prostate (15%), colorectum (10%), stom-
ach (8.5%) and liver (7.5%) cancer while, among women, are breast (25.2%), colorectum
(9.2%), lung (8.7%), cervix (7.9%) and stomach (4.8%) cancer. Globally, cancer deaths are
anticipated to keep increasing with an expected 13.1 million deaths in 2030 [115].
Cancer originates from the abnormal growth of cells that serve no purpose, and re-
ferred to as tumor. It develops from benign growth with minor genetic alteration which
1
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Figure 1.1: Data refers to the specific cause of death, which is distinguished from risk
factors for death, such as air pollution, diet and other lifestyle factors. This is shown by
cause of death as the percentage of total deaths [94].
advance, as a result of mutations that have been accumulated over time, to more aggres-
sive cancer: pre-malignant (pre-cancerous) and malignant (cancerous) tumor. In certain
scenarios, metastasis occurs. That is cancerous cells spread from the original tumor and
attack different organs and tissue. The development of cancer within an individual takes
an evolutionary process similar to the evolution of species. In the evolution of species,
individuals in a population tend to evolve by mutation and selection. By mutation, we
mean the change in the gene of a cell that can be passed to the offspring, while a selec-
tion is simply an increase in the diversity of life. Similarly, tumor evolves by mutation
and selection. However, these processes acting on cells in a tissue are caused by carcino-
gens (a substance likely to cause cancer in living tissue) [18]. The concept that explains
the reproducibility of the evolutionary process of tumor is known as tumorigenesis. In
tumorigenesis, despite the presence of confounding factors (e.g. genetic background,
micro-environment), each tumor of the same type or subtype can be seen as an indepen-
dent realisation of the same evolutionary process.
Evidence has shown that the tumor microenvironment (TME), that is, a well defined
environment composed of many components (the immune cells and growth factors)
where tumor cells can compete, have great influence on the behaviour of tumorigenic
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cells, as its components assume a major role in the development of tumor which in-
cludes tumor initiation and metastasis [7]. Furthermore, signalling molecules, such as
cytokines are also seen to play a vital role in the tumor microenvironment. They are
proteins secreted by many cell types of the immune system which mediate and regu-
late immune and inflammatory reactions in the TME. Cytokines can be grouped into
two types: the pro-inflammatory and anti-inflammatory cytokines. On one hand, the pro-
inflammatory cytokine enhances inflammation at the tumor site thereby recruiting the
immune cells for cytotoxic activity in order to eliminate or inhibits tumor growth. It,
therefore, contributes to tumor regression. On the other hand, the anti-inflammatory
cytokine reduces inflammation at the tumor site which in turn recruits immune cells in
favour of the tumor cells. It, therefore, enhances tumor progression.
1.1.2 Protein-Protein Functional Interaction (PPFI) Networks
In life science research, the interaction of biological entities, such as metabolites, pro-
teins, and genes, have emerged to be of great interest and very important. Biological
networks, such as metabolic, protein interaction and gene regulatory networks, are of-
ten used to represent interplay between different interactions [57]. Moreover, several
biological studies found that a protein does not accomplish its function alone but col-
laborate with different proteins to carry out its function. Thus, it makes processes to
be fulfilled via protein-protein functional interaction networks in living cells. These in-
teractions are biologically divided into two categories: physical and genetic interactions.
Physical contact among proteins is called physical interactions, while genetic interac-
tions between proteins consist of the mechanism through which a given protein per-
forms its functions [75].
In this thesis, we denote by protein-protein functional interactions those acquired from
knowledge about shared evolutionary history, cooexpression, pathway, physical and ge-
netic interactions. Interactions between proteins can either be direct or indirect via some
intermediates proteins thus generating a protein-protein functional interaction network [75].
In this network, nodes/vertices are proteins while edges/links are functional interaction or
connection amidst proteins of an organism. Mathematically, protein-protein functional
interaction networks are visualized as an undirected graph N (P , I), where P is the set
of proteins and I is the set of functional relationships depicting the paths of communica-
tion and metabolism of an organism. Understanding protein-protein functional interac-
tion networks might deepen our knowledge of biological systems, including molecular
pathways. Also, it help explain functions of diverse proteins in disease outcome and
elucidate essential interactions contributing to the system stability and integrity [75].
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1.2 Problem Statement
As dangerous and deadly as cancer is, there is still a gap in our understanding of the
mechanism of its establishment, recurrence cycle and elimination [37]. Many research
studies have suggested approaches which may improve treatments of cancer. Existing
treatments like surgery, chemotherapies and radiotherapies have performed key roles
in the elimination of cancer. However, these treatments do not generally guarantee a
cure, as later metastasis can occur in the patient. Over time, efforts have been made in
developing immunotherapy. This is a treatment that entails strengthening a cancer patient
immune system by enhancing its ability to recognise and fight cancer. It prevents cancer
recurrence, and its development can be controlled for a long term through a process
known as Immunosurveillance, by which the immune system search for and recognises
foreign pathogens, for example, bacteria, viruses, pre-malignant and malignant cells in
the body [37].
It has been shown that cancer stem cells are regulated by the complex interaction
components that make up the tumor microenvironment, through a network of growth
factors and cytokines [56]. Therefore, focusing on and understanding the role of this
component and the level of concentration of modulating factors present in the TME can
play a significant role in battling cancer. Many research projects have investigated the
dynamics of these cytokines about cancer in order to understand its evolution for im-
proving diagnostic, prognostic and therapeutic strategies. However, these research are
mostly restricted to cells that directly perform cytotoxic effect on cancer cells, such as
the natural killer (NK) and cytotoxic T lymphocytes (CTLs or CD8+ T) cells, and they
do not explicitly integrate cytokine-mediated innate-adaptive immunity in a tumor dy-
namics [26, 69]. Moreover, emerging abundance availability of large protein sequence
and public gene databases had been proven to have the capability to provide new in-
sights into the biology of organisms and can give rise to the enhancement of drug target
selection process by identifying genes that are extremely important to cancer growth
[75, 76]. Moreover, none of those research has combined cellular-level mathematical
models with protein-protein functional interaction network analysis, to predict essential
proteins, biological processes and enriched pathways associated with cancer disease.
1.3 Objectives of the Project
This project is aimed at identifying breast cancer disease target using mathematical mod-
elling and computational simulations of tumor microenvironment dynamics. In order
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to achieve it, the objectives are:
• Describing the tumor-immune system interaction through the network of cytokines
in the presence of cancer in the tumor microenvironment,
• Formulating and analysing the mathematical model that describes the dynamics
of tumor growth and the host immune system components in the tumor microen-
vironment,
• Identifying cytokines that play a significant role in the inhibition and activation of
immune responses leading to tumor progression and regression, respectively and
• Identifying proteins that can trigger key cytokines in the model, analysing their in-
teractions with other proteins in human, and possibly elucidate essential proteins
as a biomarker for effective treatment to eliminate breast cancer.
1.4 Outline of the Project
This project is arranged into five chapters. In Chapter 2, we explore some of the re-
lated works to this thesis by first reviewing relevant biological literature on immune
response associated to tumor growth in the tumor microenvironment, some of the pro-
posed mathematical models on the dynamics of tumor-immune interaction in the tu-
mor microenvironment, and key measures important for understanding protein-protein
functional interaction network analysis. In Chapter 3, we develop a new mathematical
model to investigate the dynamics of cancer growth and host immune system compo-
nents through a network of cytokines in the tumor microenvironment. We also perform
both analytical and numerical analysis of the model. In Chapter 4, we identify proteins
and breast cancer genes that regulate key cytokines in our model by first characteris-
ing a unified human protein-protein functional interaction network using human pro-
tein sequences database gotten from different biological data sources. Also, we suggest
essential proteins as a new development for an effective treatment to eliminate breast
cancer. Chapter 5 summarises the thesis and formulate some recommendations.
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Chapter 2
Literature Review
In this chapter, we review related works to this thesis by first reviewing the relevant
biological literature on immune response associated to tumor growth in the tumor mi-
croenvironment, review some of the proposed mathematical models on the dynamics of
tumor-immune interaction, and also present some useful measures that will be used in
the analysis of protein-protein interaction network.
2.1 The immune system
The human immune system is the system of cells, tissues and organs that work together
to defend the body against infection and toxins. There are two types of immune system:
innate and adaptive immune system.
2.1.1 The innate immune system
The innate immune system also known as non-specific immune system is regarded as the
first line of defence in our body’s immune system. It gives the initial defence against
pathogenic infections once a pathogen (bacterium or virus) attacks the body. It is acti-
vated by the presence of molecules called antigens and the chemical properties presented
by the pathogens. As shown in Figure 2.1, the innate immune cells are granulocytes
(neutrophils, eosinophil, and basophil), mast cells, complement protein, γδT cell, natu-
ral killer T cell, macrophage, dendritic cells (DCs) and natural killer cells (NK cells). The
latter three are essential in tumor recognition and shall, therefore, be used in the analysis
of the tumor microenvironment [47, 71, 100, 104].
Macrophages are derived from the process of hematopoiesis in the bone marrow. Once
they sense the presence of invaders, they are being activated and are the first type of
6
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Figure 2.1: An illustration of the immune system (https://www.nature.com/nrc/).
cells which arrive at the infection site and then undergo a process known as phagocytosis
whereby the macrophages engulf the invader and destroy it [100].
Unlike macrophages, natural killer cells do not attack pathogens directly. Instead,
once they receive a signal from the infected host cell, through the expression of specific
receptors, they are being activated and then destroy such infected host cells to stop the
spread of the infection [100]. On the other hand, dendritic cells function as the brain of
the immune system and have been seen to act as a link between the innate and the adap-
tive immune system [100]. They are therefore crucial for the activation of the adaptive
immune system.
2.1.2 The adaptive immune system
The adaptive immune system, also known as specific immune system, is a defence system
that is made up of relatively specialised cells and processes that eliminate or prevent
the development of abnormal conditions. It can recognise the antigens as it produces
memory cells and in the case where the antigen is already known, adaptive immune
cells might be more efficient than those of the innate immune [100]. Unlike the innate
immune system, the adaptive immune system depends on fewer cells, such as the B cells
and T cells, as depicted in Figure 2.1, to carry out its task.
B cells are also derived from the process of hematopoiesis in the bone marrow. They
are associated with the antibody-mediated immune response by displaying unique pro-
teins known as antibodies on their surface to recognise pathogens and tag them for de-
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struction.
However, T cells are derived from the thymus and are associated with the cell-
mediated immune response. They can recognise infected cells with the help major his-
tocompatibility complex (MHC) class I and II molecules, whose primary role is to attach
itself to antigens gotten from pathogens and display them on the cell surface for ac-
knowledgement by the appropriate T-cells [100]. T cells then use their receptor, i.e., T
cell receptor (TCR) to view the presented antigens. They are categorized into three main
types: cytotoxic T lymphocytes (CTLs), helper T cells (Th cells) and the regulatory T
cells (Treg).
• Cytotoxic T lymphocytes (CTLs) also known as CD8+ T cell primary job is to de-
stroys virus-infected cells. When a cell is being infected by a virus, peptides will
be loaded on MHC class I molecule which will then be transported on the sur-
face of the infected cells. CTLs will use their receptor to identify the infected cells
and destroy them. They need a cytokine called interleukin-2 (IL-2) for continued
proliferation, and activated Th cells are the major supplier of this cytokine [100].
• Helper T cells (Th cell) also known as CD4+ T cell secretes chemical messengers
(cytokines) that have dramatic effects on other immune system cells. They are
basically cytokine factories. Th cells are activated by first recognising its cognate
antigen displayed on MHC class II molecule [100]. Once activated, it then prolifer-
ates to build up clone composed of different types of Th cells namely: type 1 helper
T (Th1) cells, type 2 helper T (Th2) cells, type 17 helper T (Th17) cells and regulatory
T cells (Treg), whose receptors can recognise the same antigen. When these cells
become matured, they can produce cytokines needed to control and direct activ-
ities of the immune system. By doing this, Th cells help control the strength of
the CTLs response and made it capable of killing many target cells or invaders by
secreting cytokines such as tumor necrosis factor alpha (TNF-α) and interferon gamma
(IFN-γ) because they have anti-tumor and antimicrobial effects [100].
• regulatory T cells(Treg) keeps the immune system from over reacting [100].
2.2 The role of immune response in cancer
Many research studies have proved the vital role of the immune system in the control of
tumor development and progression [47, 71, 100, 104]. The immune cells coupled with
some other components in the tumor microenvironment has been seen to be useful in
fighting against tumor cells. Among the cells in the immune system, macrophages, NK
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cells, DCs and T cells have been discovered to play critical roles in the immune response
in cancer [17, 45, 46, 81, 97, 125].
2.2.1 The role of macrophages in the immune response in cancer
Macrophages are differentiated from a kind of white blood cell, called monocyte, in the
bone marrow. The function of macrophages in immune response can be described as
multifaceted. It performs the first line of defence against tumorigenesis acts by directly
killing tumor cells and producing different antitumor mediators. However, they are
capable of acquiring invasive and metastatic activities [97]. They can also be immuno-
suppressive by inhibiting inflammation or immune stimulatory at the outset of the in-
flammatory response.
They are classified into two main subsets: classical M1 macrophages and alternative
M2 macrophages. M1 macrophages are produced in response to Th1 cytokine IFN-γ and
they are known for producing pro-inflammatory cytokines such as interleukin-2 (IL-2),
interleukin-6 (IL-6), interleukin-12 (IL-12) and TNF-α. The role of M1 macrophages is to
prompt an antitumor response by activating cytotoxic activities i.e killing of pathogens
and tumor cells [46, 47, 97]. Contrarily to M1, M2 macrophages are known for pro-
tumorigenic and anti-inflammatory activities in the tumor microenvironment. They are
produced in response to Th2 cytokines interleukin-4 (IL-4) [97] and express a wide array
of anti-inflammatory cytokine interleukin-10 (IL-10) and tumor growth factor beta (TGF-
β) [47, 97].
The macrophages in a tumor are known as tumor associated macrophages (TAMs).
Once activated by cancer cells, they enhance tumor metastasis through a diverse mech-
anism such as tumor angiogenesis (i.e. the development of new blood vessels promoting
tumor growth), and tumor cell migration and invasion[89]. TAMs are similar to M2
macrophages as they contribute to pro-tumorigenic and anti-inflammatory activities in
the tumor microenvironment. They inhibit Th1, activates Th2 thereby initiating the im-
mune response to inhibit killing of tumor cells [97]. Due to poor clinical prognosis and
resistance to cancer therapy caused by TAMs, nowadays, TAMs are attractive target for
cancer therapeutic intervention. From previous research studies, it was gathered that
TAM-targeting cancer therapy should include: prevention of macrophages recruitment,
the transition of pro-tumorigenic M2 phenotype into antitumor M1 and restriction of
TAM survival [97].
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2.2.2 The role of NK cells in the immune response in cancer
NK cells have been seen to be a key player in the immune surveillance of cancer and
also able to prevent tumour growth [71, 97]. They are also involved in eradicating virus-
infected cells and tumor. They can identify targets directly via activating or inhibitory
receptors expressed on the cell surface of target cells (i.e. tumor cells). The ligand on
the surface of tumor cells which differentiated it from normal cells triggers the recep-
tors of NK cells thereby activating its cytotoxicity. NK cells are generally activated by
different stimuli, of which are made of contact to the DCs, direct involvement of NK
receptor(NKR) by stress-induced tumor molecules, and secretion of various cytokines
such as interleukin-1(IL-1), IL-2, IL-12, IL-15, IL-18, IL-21 and IFN-γ [81].
Evidence has shown that cytokines IL-2, IL-12, IL-15, IL-18, and costimulatory pro-
tein CD40 found on antigen presenting cells, enhances the NK cells effector activities.
That is, IFN-γ production, proliferation and its cytotoxicity against tumor cells [17, 97].
IFN-γ secreted by activated NK cells have powerful antitumor activities, including in-
ducing MHC class I expression and sensitizing tumor cells to CD8+ T cell killing [71].
The combination of IFN-γ and CD40 play a significant role in the stimulation of DCs
thereby enhancing IL-12 production by DCs. From Singh studies, the interaction be-
tween NK cells and DCs is vital for the augmentation of innate response and the activa-
tion of potent adaptive immunity [98].
2.2.3 The role of DCs in the immune response in cancer
Over the years, research has highlighted that the DCs is more potent in presenting anti-
gens to the T cells in order to orchestrate the antigen-specific T cells responses. Hence,
it is broadly agreed that the primary immune responses can only be initiated by the
DCs [100, 104]. That is, they can efficiently activate naive T cells, while, the B cells and
macrophages act as antigen presenting cells (APCs) in the augmentation of pre-activated
T cells and also in the activation of memory T cells.
DCs play significant roles in activating, directing and regulating adaptive immune
response. They are also critically involved in tumor immunosurveillance [104]. More-
over, some evidence in vivo have shown that tumor-infiltrating DCs are capable of recog-
nising tumor antigens which have grown to maturity in the tumor microenvironment.
Thus, they act as an effective APCs inducing a specific anti-tumor immune response.
Due to the presence of tumor cells in the microenvironment, immature DCs are activated
(or become matured) through the production of pro-inflammatory cytokine IL-12 made
by activated macrophages. Matured DCs then present tumor antigens onto MHC class I
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and II molecules displayed on its surface. Following the uptake, mature DCs then locate
and activates cognate naive and central memory T cells in the draining lymph nodes.
Licensing of mature DCs (i.e., the interaction of mature DCs with activated CD4+ T cells
or NKT cells through CD40 on the surface of DCs, and costimulatory protein CD40L on
the surface of CD4+ T cells) is firmly believed to be able to activates naive CD8+ T cells
efficiently. Otherwise, the CD8+ T cells may function as an effector cell just for little
lifespan [104].
2.2.4 The role of T cells in the immune response in cancer
The adaptive immune system performs a crucial role with regards to the host ability to
produce an effective antigen-specific immune response against tumors [90]. The helper
T cells (CD4+ T cells) assume a vital role at the onset of adaptive immune response. They
usually recognise peptides bound to MHC class II molecules on APCs which include
dendritic cells, macrophages and B cells [45, 125]. From studies, it has been demon-
strated that when tumors exhibit antigens which differentiated them from normal cells,
they can be recognised by effector T cells of the adaptive immune system and prompt
antitumor immune response in both human system and experimental mice [31]. As
mentioned earlier, the naive helper T (Th0) cells develop into clone of effector subsets,
namely: the type 1 helper T cells (Th1 cells), type 2 helper T cells (Th2 cells), type 17
helper T cells (Th17 cells) and regulatory T cells (Treg) upon activation. Each subset can
be characterized on the source of cytokines they secrete. For example, Th1 cells secrete
IFN-γ, Th2 cells secrete IL-4, Th17 cells secretes IL-17, and Treg secretes IL-10 which can
modulate the function of other T cells [125].
Among the activated helper T cell subsets, Th1 cells have been seen to be one of the
most promising in producing an antitumor immune response. Upon antigen encounter,
Th1 cells produce a large amount of IFN-γ and also secrete pro-inflammatory cytokines
including IL-2, TNF-α, and IFN-γ. On the other hand, Th2 cells are well-known for
producing anti-inflammatory cytokines, such as IL-4, IL-5 and IL-13, and are in charge
of coordinating humoral immunity responses. However, cytokines such as IL-6, TGF-
β, IL-17, IL-21, and IL-23 are associated with Th17 cells, and they contribute to tumor
progression and carcinogenesis in the context of chronic inflammation and infection [31].
From several studies, it has been gathered that positive clinical outcome can be allot-
ted to Th1 effector cell infiltrating within tumors of patients with various cancer, in the
sense that Th1 cells can control tumors through the secretion of IFN-γ which directly or
indirectly affected immune activation and modulation. IFN-γ can also induce priming
and maturation of cytotoxic activity of CTLs through the activation of DCs in the tumor
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microenvironment and further prompt the elimination of tumor through activation of
NK cells and M1 macrophages [86].
Universally, cytotoxic T lymphocytes (CTLs) also known as CD8+ T cells is known to
be the primary executor of effective anti-tumor T cell responses in the adaptive immune
system due to its cytotoxic activity in the tumor microenvironment. It has been observed
that tumors which evade CD8+ T cells attack might have down-regulated the expression
of MHC class I antigen. Moreover, CD8+ T cell was shown to still maintain their anti-
tumor effect in the absence of CD4+ T cells, it can only last for limited time because the
role of CD4+ T cells is to improve the efficiency of CD8+ T cells, thereby creating and
sustaining long-term CD8+ memory T cells response [45].
Also, CD4+ T cells help in the activation and influence the differentiation and ex-
pansion of antigen-specific CTLs. Some evidence has suggested a direct role of effector
CD4+ T cell subsets in inhibiting tumor growth and production through the secretion
of pro-inflammatory cytokines TNF-α and IFN-γ or direct cytolytic activity. This activ-
ity occurs by de-granulation of cytotoxic granule that contains toxic effector molecules,
such as perforin and granzymes [107] or ligation of Fas Ligand(FasL) apoptotic killing
pathway. This shows that CD4+ T cells can eliminate tumor cells in the absence of CD8+
T cells.
2.2.5 The role of cytokines secreted by innate immune cells in the TME
In the tumor microenvironment, the resting macrophages can differentiate the tumor
cells from the normal cells due to the antigen presented on them. They are activated
with the aid of pro-inflammatory cytokines IFN-γ [46]. The activated macrophage reacts
by undergoing a process known as phagocytosis thereby eliminating the tumor cells.
Activated macrophages as already mentioned, are classified into two subtypes: M1
macrophages and M2 macrophages. M2 macrophages secrete anti-inflammatory cy-
tokines, such as IL-10, TGF-β, IL-4 and IL-13, which are responsible for tumor progres-
sion and metastasis. Also, these cytokines facilitate the transition of M1 macrophages
to M2 macrophages. Expression of IL-10 by M2 macrophages can help promote the
production of IL-4 and IL-13 in Th2 cells [47]. On the contrary, M1 macrophages role
is to cause an antitumor response by triggering cytotoxic activities and secreting pro-
inflammatory cytokine IL-12 and IFN-γ. They also secrete IL-23 which develops and
causes expansion of Th17 cells secreting IL-17, thereby contributing to inflammatory
autoimmune pathologies[47].
The production of IL-12 by M1 macrophages in the tumor microenvironment acti-
vates the immature dendritic cells (iDCs). Following the uptake of tumor antigen pre-
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sented onto the MHC class I and MHC class II molecules on themselves, they go through
maturation and becomes mature DCs (mDCs). Through the secretion of IL-12 and also
through pattern recognition receptor exhibited by the naive T cells upon identifying
peptides produced by DCs, the cognate naive and central memory T cells composed of
the CD4+ T cells and CD8+ T cells become activated [31, 104].
Figure 2.2: Activities of immune cells in the tumor microenvironment.
2.2.6 The role of cytokines secreted by adaptive immune cells in the TME
As illustrated in the schematic diagram Figure 2.2, naive CD4+ T cells (Th0) are activated
as a result of signals received from APCs such as dendritic cells or M1 macrophages
upon encounter with antigen. After activation, CD4+ T cells differentiate into a clone of
its subsets namely: Th1, Th2, Th17, and Treg, with each type having distinct cytokines
secretion for a specific function in the tumor microenvironment [53] as shown in Fig-
ure 2.3.
Th1 cells development pathway is typically driven by IL-12, while Th2 cells arise as
a result of an environment rich in IL-4 [13]. Th1 cells secrete IL-2 which acts as growth
factor thereby enhancing the continued proliferation of Th1, NK and CD8+ T cells in
the TME. IL-2 secretion also stimulates the generation of IFN-γ by Th1 and prevent
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activated cells from regressing to an inactive state. Furthermore, Th1 cells secrete IFN-
γ and TNF-α, thereby enhancing cytotoxic capabilities of immune cells including M1
macrophages, NK cells and CD8+ T cells to cancerous cells [13, 53]. Synergistically
with TNF-α, the secretion of IFN-γ mediates cytotoxicity of tumor cells by inducing
reactive oxygen species and inhibiting angiogenesis [125]. As already mentioned, Th2
cells are known for producing anti-inflammatory cytokines, such as IL-4, IL-5, and IL-
13. All these cytokines promote M2 macrophages phenotype. In particular, IL-4 is as an
autocrine growth factor for Th2 cells [120].
Figure 2.3: Th0 cells differentiation into clone of effector subsets.
Cytokine TGF-β and IL-6 enhances the differentiation of Th0 cells into Th17 cells.
Th17 cells also proliferate by secreting IL-21 which further increase Th17 generation in
an autocrine manner. IL-23, secreted by Th17 cells, also promotes the proliferation and
inflammatory activity of Th17. Also, Th17 cells secrete IL-17 which promotes maturation
of DCs family and induce IL-12 production from macrophages, thereby promoting CTLs
activation [31].
However, regulatory T cells (Treg) depend on TGF-β for their differentiation. After
differentiation, they secrete TGF-β which inhibits the Th1 and Th2 cells differentiation
and also secrete IL-10 which promotes the proliferation of Th2-cytokines and inhibits
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the proliferation of Th1-cytokines [2]. Several studies indicate IL-10 as a negative medi-
ator in the cross-talk among the innate and adaptive anti-tumor immune response. They
are known to hold APCs by inhibiting MHC molecules, down-regulating IL-12 produc-
tion and inhibiting DCs maturation and differentiation as shown in Figure 2.2. They
can potentially limit the protumor/antitumor effects of Th17 mediated inflammation,
specifically by interacting with IL-10 receptors of Th17 cells [31]. IL-10 can also reduce
the ability of CD8+ T cells in eliminating cancer cells [67].
CD8+ T cells secrete cytokine TNF-α and IFN-γ which enhance and strengthen its
cytotoxic function against tumor cells. The combination of the two cytokines drives
tumor cell into deterioration. Likewise, the natural killer cells induce direct killing of
the tumor cells once they have been activated either through the secretion of IL-2 or its
activated receptor as a result of recognition of tumor antigen presented on the tumor
cells. They also secrete cytokine TNF-α and IFN-γ, thereby enhancing the cytotoxic
effect made on the tumor cell leading to tumor regression [17]. NK cells also help at a
later stage of tumor growth by acting as an aide in the priming process of Th1 and CD8+
T cells through IFN-γ production [2].
2.2.7 The role of cytokines in cancer cells growth
Cancer cells inhibit IFN-γ production and paralyze antitumor effector cells (NK cells,
CD8+ T cells and M1 macrophages) through the secretion of immuno-suppressive fac-
tors, including IL-10, IL-6, VEGF (Vascular endothelial growth factor) and TGF-β [7].
Cytokines, secreted by M2 macrophages and Th2 cells, also contributes to tumor initi-
ation, progression and metastasis. As the population of tumor grows very large in the
microenvironment, tumor cells tend to lack oxygen. They, therefore, produce TGF-β,
thereby encouraging angiogenesis and avoid the immune response which leads to tu-
mor escape [50]. Interestingly, cytokine IL-23 is produced not only by DCs and macrophages,
but also by cancer cells. As IL-12 acts on naive CD4+ T cells, IL-23 also acts on mem-
ory CD4+ T cells [38]. IL-23 has been shown to effectively suppress innate antitumor
response and acts as an important molecular driver of Th17 cells [105]. Besides, IL-23
induces immunosuppression through down-regulation of CD4+ and CD8+ T cells infil-
trating in tumor tissues [80].
2.3 Modelling tumors and the immune system
Over many years of research on anticancer immunotherapy, several mathematical mod-
els have been developed and analysed [26, 50, 54, 69]. Here, we explore some of the
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important papers in the mathematical modelling of tumor-immune interaction. We
concentrate on these papers because some of their ideas were used in formulating our
model.
Kirschner and Panetta (1998) in their paper on modelling immunotherapy of the
tumor-immune interaction, presented a mathematical model representing the dynamics
between tumor cells, immune-immune-effector cells coupled with IL-2 dynamics. The
result from their model shows that tumor cells elimination can only be done by com-
bining both adoptive cellular immunotherapy (ACI) and administration of the cytokine
IL-2. It, therefore, emphasizes the crucial role of cytokine-enhanced immune function in
cancer treatment [54]. Furthermore, Baloni and Us (2013) built on the existing model and
developed a mathematical model of tumor and immune-effector cells with scheduled
chemotherapy. They concluded that the effect of scheduled IL-2 dose with chemother-
apy and adoptive cellular immunotherapy reduces tumor growth [8].
De Pillis and Radunskaya (2003) in their paper formulated a mathematical model of
tumor growth with the aim of addressing some arising questions concerning the mech-
anisms implicated in the immune response to a tumor challenge. The model is in the
form of a system of ordinary differential equations (ODEs) focusing on the interaction
between NK cells and CD8+ T cells with tumor cells. It explores the dynamics of tu-
mor escape as well as describes the development of immunity to upcoming tumor chal-
lenges [26].
Arciero et al. (2004) presented a mathematical model of a nonlinear system of ODEs
describing the growth, immune escape and siRNA treatment of tumors. In their paper,
they pointed out the vital role of pro-inflammatory and anti-inflammatory cytokines in
cancer research. They used pro-inflammatory cytokine IL-2 and anti-inflammatory cy-
tokine TGF-β as a case study. The interactions among immune cells, tumor cells and
cytokine IL-2 and TGF-β were described. The results depict the pro-tumor activity of
TGF-β. It weakens the immune system by reducing tumor antigen expression, thereby
hindering the activation of immune effector cells. This results in the stimulation of tu-
mor growth by promoting angiogenesis and its ability to escape host detection. The
inclusion of siRNA treatment reduces TGF-β production by targeting the miRNA that
codes for TGF-β. It thereby reduces the presence and the effect of TGF-β in the tumor
cells, which, in turn, suppress the tumor cell [50].
Later on, de Pillis et al. (2006) advance by developing a mathematical model of
a system of ODEs governing tumor development on a cell population level coupled
with the combination of chemotherapy, vaccine and immunotherapy treatments. The
situation whereby neither chemotherapy nor immunotherapy alone can be enough to
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control tumor growth was established. They concluded that a combination of these
therapies could lead to the eradication of tumors [27].
On the other hand, Robertson-Tessi et al. (2012) in their paper proposed a mathe-
matical model of the interaction between tumor growth and immune system (including
the main cell populations implicated in effector T-cell mediated tumor killing, i.e., the
regulatory T cells (Tregs), helper T cells and dendritic cells). Multiple mechanisms of im-
munosuppression, such as cytokines and growth factors, which regulates the interaction
between the cell population, were incorporated. Their report demonstrated the effect of
Tregs and TGF-β on different classes of tumors. Access to fully grown tumor size by fac-
tors, such as TGF-β, induced immunosuppression, the transformation of helper T cells
to Tregs, and limitation of the immune cell was shown to lead to tumor escape [91].
Moreover, Awang and Maan (2016) proposed a new mathematical model focusing on
the function of NK cells and CD8+ T cells in tumor-immune interaction. They included
a subdivision of the tumor population into interphase and mitosis. Like others, they also
discovered that immune suppression made by NK cells and CD8+ T cells in the model
greatly helps to stabilize the system and further inhibits the growth of tumor cells [6].
Mahasa et al. (2016) in their paper presented a mathematical model which involves
different tumor cell and immune cell population. Their model depicts the progression
and survival of tumor cells upon encounter with the immune system. This process is
mediated by the activated CD8+ T cells and natural killer cells. They came up with
predictions showing that recruitment of NK-cells from an external source might perform
a vital role in strengthening NK-cell immune surveillance. They also predicted that
inhibition of tumor cells progression could not be efficiently carried out alone by the
host immune system, but with addition of some external factors [69].
Most of the research studies that have been carried out of which few are reviewed
above, only focus on modelling tumor-immune dynamics by considering the interaction
in some specific host immune system, which was shown by Mahasa et al. (2016) to be
ineffective against tumor cell progression. It is because there are some hidden factors
that have not been considered while performing the analysis. These factors are complex
interaction components found in the tumor microenvironment. They regulate cancer
stem cells through network of cytokines and growth factors. Therefore in this research,
key components, such as various immune cells and cytokines which made up the tumor
microenvironment and in one way or the other contributes to tumor formation includ-
ing tumor initiation and metastasis, will be incorporated in the formation of our new
mathematical model to further investigate the dynamics of tumor-immune interaction.
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2.4 Centrality Analysis Methods for Biological Networks
For a better understanding of the biological organization of humans from its protein
functional network and probably use it as a means to establish effective treatment strate-
gies for diseases, it is required to fully have an understanding of the network structure
and how each protein contributes to the system biological processes [75]. For this rea-
son, network centrality measures are used to identify proteins which are likely signif-
icant to the functioning of the system thereby contributing to the survival of humans
and organisms. Different measures have been employed from other fields of science in
order to understand the influences of nodes in a network. Of these measures are the
centrality analysis measures of networks. In biology, centrality analysis is essential in
analysing biological networks, and it is mainly used to identify key players in biological
processes [57]
In the analysis of network, in particular biological network, it is essential to identify
the most central node that influences the topology of the network based on the question
at hand. In the course of this research, proteins are nodes while functional interaction or
connection between proteins are edges. As stated earlier, among the centrality measure
available, the following measures will be needed in our study.
We denote P(P , I) the functional network of proteins of an organism with P the
set of nodes (i.e., interacting proteins) and I the set of links (i.e., functional interaction
between proteins).
1. The degree centrality measure, Cd(i), of a protein i is the number of edges incident
to protein i. It is considered as a measure of a protein influence in the functional
network. In other words, the more the degree of a protein is the greater the number
of processes it might be involved in. In 2001 Jeong et al. used degree centrality to
correlate the degree of a protein in a network of which if removed from the protein-
protein interaction (PPI) network can lead to lethality [57]. Mathematically, degree
centrality Cd(i) of a node i is given [75] by
Cd(i) = deg(i) = ∑
j∈P
ζ(i, j), (2.4.1)
where
ζ(i, j) =
1 if (i, j) ∈ I ,0 else.
2. The closeness centrality measure of a protein i, Cclo(i), is a centrality measure
which indicates how important a protein is by how quickly it communicate with
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every nodes of the network, or how close the node is to its neighbours. It uses
average distance of a protein to all other proteins and it is defined as the reciprocal
of this sum. In other words, closeness centrality measure Cclo(i) of a node i is given
by
Cclo(i) =
nc − 1
∑j∈P dist(i, j)
(2.4.2)
where dist(i, j) is the distance or shortest path between the nodes i and j and nc
is the number of node in the connected component containing i. The normalized
closeness centrality is given by
(lc − 1)
(nc − 1)Cclo(i)
where lc is the number of link in the connected component containing i [75].
3. The betweenness centrality measure, Cb(w), of a protein w is the proportion of
of shortest paths that passes through it. It measures the influence of w with re-
gards to other proteins in the functional network. That is, it shows the value of the
given protein in the communication between proteins. Mathematically, between-
ness centrality of a node w is given by
Cb(w) = ∑
i,j∈Pw
σij(w)
σij
(2.4.3)
where σij is the total number of shortest paths between i and j, σij(w) is the number
of shortest paths from i to j that passes through w, and Pw = {(i, j) ∈ P ×P : w 6=
i 6= j} [75] .
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Modelling TME Components
Dynamics
Mathematical modelling of biological processes is often used to deepen our understand-
ing of dynamics that is essential for an immune response. In this chapter, we focused
on the most important immune cells and cytokines that have been identified to play a
crucial role in cancer. The innate and adaptive immune cells under consideration are:
the resting macrophages or monocytes (M0), M1 macrophages, M2 macrophages, natu-
ral killer (NK) cells, dendritic cells (DCs), helper T cells (CD4+ T cells) and its subsets,
effector T cells (CD8+ T cells) and tumor cells [26, 50, 54, 69]. The cytokines and growth
factors used are IL-2, IL-4, IL-5, IL-6, IL-4, IL-10, IL-12, IL-13, IL-17, IL-21, IL-23, TNF-α,
TGF-β, and IFN-γ. We developed a new mathematical model describing the dynamics
of cancer growth and the host immune system components in the tumor microenviron-
ment. In addition to this, we performed the analytical and numerical analysis of the
model.
3.1 Model Description and Assumptions
The formulation of our model is presented using nonlinear ordinary differential equa-
tions (ODEs) by considering the dynamics of the population of immune cells, tumor
cells, and cytokines with respect to time t in the tumor microenvironment. Figure 3.1 de-
picts a schematic diagram describing the cytokine-mediated innate-adaptive immunity
in a tumor dynamics. Below, we explain the stepwise formation of the model equation.
The model variables and parameters used are summarised in Table 3.1 and Table 3.2,
respectively.
20
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Table 3.1: Description and units of variables used in the model
Variables Description Units
M0 Density of resting macrophages cells/ml
M1 Density of pro-inflammatory tumor associated macrophages cells/ml
M2 Density of anti-inflammatory tumor associated macrophages cells/ml
N Density of natural killer cells cells/ml
D Density of dendritic cells cells/ml
T8 Density of CD8+ cells cells/ml
T0 Density of the naive CD4+ (helper) T cells (Th0) cells/ml
T1 Density of type-1-helper T cells (Th1) cells/ml
T2 Density of type-2-helper T cells (Th2) cells/ml
T17 Density of type-17-helper T cells (Th2) cells/ml
C Density of tumor cells cells/ml
I2 Concentration of interleukin-2 (IL-2) pg/ml
I4 Concentration of interleukin-4 (IL-4) pg/ml
I6 Concentration of interleukin-4 (IL-6) pg/ml
I10 Concentration of interleukin-10 (IL-10) pg/ml
I12 Concentration of interleukin-12 (IL-12) pg/ml
I13 Concentration of interleukin-13 (IL-13) pg/ml
I17 Concentration of interleukin-4 (IL-17) pg/ml
I21 Concentration of interleukin-10 (IL-21) pg/ml
I23 Concentration of interleukin-12 (IL-23) pg/ml
Iγ Concentration of interferon-gamma (IFN-γ) pg/ml
Tα Concentration of tumor necrosis factor-α (TNF-α) pg/ml
Tβ Concentration of transforming growth factor-β (TGF-β) pg/ml
3.1.1 Immune Cells Equations
Resting macrophages (M0)
dM0
dt
= m− α1 IγM0 − α2M0C− δ0M0. (3.1.1)
Equation (3.1.1) represents the dynamics of resting macrophages in the TME. Parameter
m is the constant supply rate for macrophages which represents the fact that macrophages
as one of the innate immune cells, are constantly present within the host body even in the
absence of tumor. As mentioned earlier, once they are activated as a result of the pres-
ence of tumor cells in the TME, they polarized into two phenotypes: M1 macrophages
and M2 macrophages. They respectively polarized at a rate α1 and α2 due to the presence
of pro-inflammatory cytokine IFN-γ and tumor cells. The parameter δ0 is the natural de-
cay rate of the resting macrophages.
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Table 3.2: Description and units of parameters used in the model
Parameter Description Units
d External influx rate of DCs cells/ml/day
m External influx rate of macrophages cells/ml/day
n External influx rate of NK cells cells/ml/day
σ0 Constant supply of Th0 cells upon activation cells/ml/day
σ8 Constant supply of CD8+ T cells upon activation cells/ml/day
ρ1 Proliferation rate of M1 Macrophages day−1
ρ3 Proliferation rate of Th1 cell day−1
ρ4 Proliferation rate of Th2 cell day−1
ρ5 Proliferation rate of Th17 cell day−1
ρn Proliferation rate of NK cells day−1
ρd Proliferation rate of DCs day−1
ρt Proliferation rate of CD8+ T cells day−1
η Half saturation constant of the immune response
τ Transition rate from M1 to M2 Macrophages by anti-inflammatory cytokines day−1
βn Inactivation rate of NK cells by tumor cells day−1 cell−1
β1 Inactivation rate of Th1 cells by tumor cells day−1 cell−1
β8 Inactivation rate of CD8+ T cells by tumor cells day−1 cell−1
θ1 Intrinsic growth rate of tumor cells day−1
θ2 Maximum carrying capacity of tumor cells cell−1
αm Expansion rate of tumor cells by M2 macrophages day−1
γ1 Expansion rate of NK and Th1 cells enhanced by IL-2 day−1
γ2 Expansion rate of dendritic cells enhanced by IL-12 and IL-17 day−1
γ3 Expansion rate of Th2 cells enhanced by IL-4 and IL-10 day−1
γ4 Expansion rate of Th17 cells enhanced by IL-21 and IL-23 day−1
γ5 Expansion rate of CD8+ T cells by enhanced IL-2 and IL-17 day−1
α1 Polarization of resting macrophages into M1 cells/ml/day
α2 Polarization of resting macrophages into M2 cells/ml/day
αt Activation rate of T cells cells/ml/day
ζ ′is Th0 differentiation into it subsets cells/ml/day
δ′i s Apoptosis rate of macrophage phenotypes day
−1
δn Apoptosis rate of NK cells day−1
δd Apoptosis rate of DCs day−1
µ′is Apoptosis rate of Th0 cell and its subsets day
−1
µ8 Apoptosis rate of CD8+ T cells day−1
Φ Elimination rate of tumor cells by immune effector cells day−1
µc Apoptosis rate of tumor cells by TNF-α day−1
µe Apoptosis rate of M2 macrophages by IFN-γ day−1
hγ Inhibition measure by IFN-γ day−1
hβ Inhibition measure by TGF-β day−1
h10 Inhibition measure by IL-10 day−1
ν′i s Production rate of tumor suppressing cytokines by immune cells pg/cell/day
ν′js Production rate of tumor promoting cytokines by immune cells pg/cell/day
ν′ks Production rate of tumor promoting cytokines by tumor cells pg/cell/day
δs Decay rate of tumor suppressing cytokines day−1
δp Decay rate of tumor promoting cytokines day−1
M1 macrophages (M1)
dM1
dt
= α1 IγM0 +
ρ1M1C
η + C
− τ(I4 + I13 + I6 + Tβ)M1 − δ1M1. (3.1.2)
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Figure 3.1: A schematic diagram of cytokine-mediated innate-adaptive immunity in a
tumor dynamics. C∗ = Cη+C . All variables and parameters shown in this figure are
presented in Table 3.1 and 3.2. On most interaction arrows where the formula of the
interaction is not given, we place on one side the variable(s) and on the other side the
parameters(s) participating.
Equation (3.1.2) represents the dynamics of M1 macrophages in the TME. Parameter α1
is the activation rate of M1 macrophages by IFN-γ. Once they are activated, they prolif-
erate as represented in the second term in Michaelis-Menten form which describes the
growth of immune cells in response to tumor cells. ρ1 represents the proliferation rate
of M1 macrophages due to stimulus and η the half saturation constant of the immune
response. M1 macrophages undergo phagocytosis where they bind with the tumor cells
by engulfing them and preparing them for death. The third term depicts the transition
from M1 macrophages to M2 macrophages through anti-inflammatory cytokine IL-4,
IL-13, IL-6 and TGF-β produced by Th2 cells and tumor cells respectively. Parameter τ
is the transition rate from M1 to M2 [67] and δ1 in the last term is the natural decay rate
of M1 macrophages.
M2 macrophages (M2)
dM2
dt
= α2M0C + τ(I4 + I13 + I6 + Tβ)M1 − µe IγM2 − δ2M2. (3.1.3)
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Equation (3.1.3) represents the dynamics of M2 macrophages also known as anti-inflammatory
macrophages in the TME. Parameter α2 is the activation rate of M2 macrophages by
tumor cells. The second term as explained above is the transition from M1 to M2
macrophages thereby promoting the growth of tumor cells in the TME. The third term
depicts the elimination of M2 macrophages by pro-inflammatory cytokine IFN-γ at a
rate µe and δ2 is the natural decay rate of M2 macrophages.
Natural killer cells (N)
dN
dt
= n +
ρnNC
η + C
+
γ1 I2C
1+ hβTβ
− βnNC− δnN. (3.1.4)
Nk cells are being supplied to the tumor site at a constant source n since they are nor-
mally present in the host body even in the absence of tumor cells in the TME. In the
presence of tumor cells, NK cells are activated and proceed to proliferate in order to
perform their cytotoxic activity. The proliferation made by NK cells in the TME due to
stimulus is represented by the Michaelis-Menten form ρn NCη+C . ρn stands for the prolifer-
ation rate of NK cells and η the half saturation constant of the immune response. This
model makes sense because the proliferation of tumor-specific effector cells are triggered
due to the presence of tumor cells but attains a saturation level at tumor population [6].
As depicted in the third term, IL-2 promotes NK cells proliferation at the tumor site
with proliferation rate γ1. This process is inhibited by TGF-β with inhibition measure hβ
[7, 17]. The fourth term represents the local interaction or binding of NK cells to tumor
cells with a binding rate βn. This interaction can either result into programming tumor
for lysis(i.e., death) or resulting to inactivation or killing of Nk cells [69]. δn is the natural
decay rate of NK cells.
Dendritric cells (D)
dD
dt
= d +
ρdDC
η + C
+
γ2(I12 + I17)C
1+ hβTβ + h10 I10
− δdD. (3.1.5)
Parameter d in Equation (3.1.5) is assumed to be the constant supply rate of dendritic
cells. The proliferation process is represented by the second term in Michaelis-Mentens
form as explained in the previous equations where ρd represents the proliferation rate
of DCs and η the half saturation constant of the immune response. Cytokine IL-12 and
IL-17 promotes DCs activation with parameter γ2 and this process is inhibited by anti-
inflammatory cytokines IL-10 and TGF-β at rate h10 and hβ, respectively [31, 104]. δd in
the last term is the decay rate of DCs.
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CD4+ T cells (T0)
dT0
dt
= αt I12D + σ0 − ζ1 I12T01+ hβTβ −
ζ2M2T0
1+ hβTβ
− ζ3(I6 + Tβ)T0
1+ h10 I10
− µ0T0. (3.1.6)
The DCs activate naive helper T cell(Th0) by secreting IL-12 at rate αt[31, 104]. σ0 in
the second is the initial supply of CD4+ T cells recruited to the tumor site. Parameter
ζ1, ζ2 , and ζ3 are the differentiation rates of Th0 into its subsets Th1,Th2 and Th17 upon
encounter with IL-12, M2 macrophages, and IL-6 and TGF-β, respectively[13, 31]. hβ
measures the inhibition rate of Th1 and Th2 by TGF-β while h10 measure inhibition of
Th17 differentiation by IL-10 [2]. In order to simplify the model, we do not represent the
assumption that Th0 differentiated into Treg. Hence, the last term depicts the natural
decay of Th0 cells with rate µ0.
Th1 cells (T1)
dT1
dt
=
ζ1 I12T0
1+ hβTβ
+
ρ3T1C
η + C
+
γ1 I2C
1+ h10 I10
− β1T1C− µ1T1 (3.1.7)
Equation (3.1.7) represents the dynamics of Th1 cells with the first term representing
Th0 differentiating into Th1 as explained in Equation (3.1.6). After differentiation, Th1
cells proliferate in order to secrete pro-inflammatory cytokines in the TME. This process
is represented using Michaelis-Mentens form as previously explained in the equations
above. Parameter ρ3 represents the proliferation rate of Th1 cells, and the half satura-
tion constant of the immune response is η. Moreover, in the third term, cytokine IL-2
enhances Th1 cells proliferation at the rate γ1. This process is inhibited by IL-10 with
inhibition measure h10 [2]. The fourth term stands for the inactivation of Th1 cells upon
encounter with tumor cells with rate β1 [53]. The last term is the decay of Th1 cells with
rate µ1.
Th2 cells (T2)
dT2
dt
=
ζ2M2T0
1+ hβTβ
+
ρ4T2C
η + C
+
γ3(I4 + I10)C
(1+ hγ Iγ)
− µ2T2 (3.1.8)
The first term in Equation (3.1.8) shows the differentiation of Th0 into Th2 as explained
in Equation (3.1.6). Likewise, Th2 cells proliferation are represented using the Michaelis-
Mentens form as previously explained where ρ4 represents the proliferation rate of Th2
cells. The half-saturation constant of the immune response is η thereby secreting anti-
inflammatory cytokines in the TME. Th2 cells proliferation is potentiated by IL-4 and
promoted by IL-10 with rate γ3 and this is inhibited by IFN-γ with parameter hγ [13].
The last term is the decay of Th2 cells at a rate µ2.
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Th17 cells (T17)
dT17
dt
=
ζ3(I6 + Tβ)T0
1+ h10 I10
+
ρ5T17C
η + C
+ γ4(I21 + I23)C− µ17T17 (3.1.9)
Equation (3.1.9) represents the dynamics of Th17 cells. Its the first term represents Th0
differentiating into Th17 as explained in Equation (3.1.6). Th17 cells proliferation are
modelled using the Michaelis-Mentens form as previously explained in the equations
above. ρ5 represents the proliferation rate of Th17 cells and η the half saturation constant
of the immune response. Cytokine IL-23 and IL-21 promote th17 cells proliferation and
expansion at the rate γ4 [31]. Lastly, Th17 cells decay at a rate of µ17.
CD8+ T cells (T8)
dT8
dt
= αt I12D + σ8 +
ρtT8C
η + C
+
γ5(I2 + I17)C
1+ hβTβ + h10 I10
− β8T8C− µ8T8 (3.1.10)
The DCs activate CD8+ T cells(CD8+ T cells) by secreting IL-12 at rate αt. After ac-
tivation, CD8+ T cells are recruited to the tumor site with initial supply σ8. It then
proliferates to carry out its cytotoxic activity on tumor cells. The third term, that is, the
Michaelis-Menten form represents the proliferation of CD8+ T cells in the TME with ρt
representing the proliferation rate of CD8+ T cells and η the half saturation constant of
the immune response. This process is further enhanced and promoted by IL-2 and IL-17
with rate γ5 which are further inhibited by IL-10 and TGF-β with inhibition measure h10
and hβ, respectively [2, 53, 67]. Likewise, the fourth term represents the local interaction
or binding of CD8+ T cells to tumor cells with a binding rate β8. This interaction can
either result into programming tumor for lysis or resulting to inactivation or killing of
CD8+ T cells [69]. Lastly, µ8 is the decay rate of CD8+ T cells.
3.1.2 Cancer Cell Equation (C)
dC
dt
= θ1C(1− θ2C) + αm M2 −Φ (M1 + N + T8)C− µcTαC (3.1.11)
The growth of tumor cells is modelled by the logistic term as depicted in the first term
of Equation (3.1.11) which account for the deceleration in the growth of tumor cell as
its size increases. Here θ1 and θ2 are the growth rate and carrying capacity of the tu-
mor cells, respectively [34]. The second term depicts the fact that anti-inflammatory
macrophages (M2) which function as the tumor associated macrophages (TAM) con-
tributes to the growth of tumor cells pending their existence in the tumor microenviron-
ment with parameter αm. The third term is the local interaction between immune cells
and tumor cells thereby bringing about their cytotoxic effect on the tumor cells at a rate
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Φ. The last term shows that tumor cells are killed through the secretion of tumor sup-
pressing cytokine TNF-α where µc is the elimination rate of tumor cells by TNF-α [34].
3.1.3 Cytokine Equation
dI2
dt
= ν2T1 − δs I2, (3.1.12)
dI4
dt
= ν4T2 − δp I4, (3.1.13)
dI6
dt
= ν6C− δc I6, (3.1.14)
dI10
dt
= ν10M2 − δp I10, (3.1.15)
dI12
dt
= ν12M1 − δs I12, (3.1.16)
dI13
dt
= ν13T2 − δp I13, (3.1.17)
dI17
dt
= ν17T17 − δs I17, (3.1.18)
dI21
dt
= ν21T17 − δs I21, (3.1.19)
dI23
dt
= νcC + ν23T17 − δp I23, (3.1.20)
dTα
dt
= ναT1 − δsTα, (3.1.21)
dTβ
dt
= νβC− δcTβ, (3.1.22)
dIγ
dt
= νγT1 − δs Iγ. (3.1.23)
For simplicity, we assume that the cytokines are secreted by corresponding cells in
TME at a constant rate. Here, IL-2, IFN-γ and TNF-α are produced by Th1 cells [13, 53],
IL-12 is mainly produced by M1 macrophages [31, 47], IL-17 and IL-21 are produced by
Th17 cells, IL-4, IL-5 and Il-13 are produced by Th2 cells [31, 120], IL-6 and TGF-β are
produced by tumor cells [67], IL-10 is produced by M2 macrophages [47, 67] and IL-23
is produced by tumor cells and Th17 cells [31, 38, 47, 105]. All the νi’s are the production
rates of cytokines and δi’s are their respective natural decay rates. Each parameter from
Equation (3.1.1) to Equation (3.1.20) is assumed to be positive.
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3.2 Model Reduction
From previous research, the growth of tumor cells involves numerous time scales which
occurs roughly on weeks to months in vitro while in vivo, it takes a time interval of
months to years. Recruitment of the immune cells under consideration occur on a time
interval of days to weeks and secretion of inflammatory cytokines by these cells only
occur on time interval of seconds to hours [67, 69]. In order to clearly understand the
dynamics of tumor cells growth, we simplify the model using quasi steady state approx-
imation (QSSA) for the concentration of the inflammatory cytokines by assuming that
there is no change in concentration in time for all cytokines produced since they have a
limited time of existence. Hence, from Equations (3.1.12)-(3.1.20) we have:
I2 = ν2δs T1,
I4 = ν4δp T2,
I6 = ν6δp C,
I10 = ν10δp M2,
I12 = ν12δs M1,
I13 = ν13δp T2,
I17 = ν17δs T17,
I21 = ν21δs T17,
I23 = νcδp C +
ν23
δp
T17,
Tα = ναδs T1,
Tβ =
νβ
δp
C,
Iγ =
νγ
δs
T1.
We substituted these expressions into Equations (3.1.1)-(3.1.11) and assumed that
the secretion of those cytokines produced by more than one immune cells varies. In
order to further simplify the model, we neglected the cells with a lesser secretion of
such cytokines. Hence, we obtain the following simplified model for cell dynamics in
the tumor microenvironment.
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
dM0
dt
= m− κM0T1 − α2M0C− δ0M0,
dM1
dt
= κM0T1 +
ρ1M1C
η + C
− (λT2 + ϕ1C)M1 − δ1M1,
dM2
dt
= α2M0C + (λT2 + ϕ1C)M1 − ξtT1M2 − δ2M2,
dN
dt
= n +
ρnNC
η + C
+
ε1T1C
1+ ξcC
− βnNC− δnN,
dD
dt
= d +
ρdDC
η + C
+
(ε2M1 + ε7T17)C
1+ ξcC + ξ2M2
− δdD,
dT0
dt
= ωM1D + σ0 − ξd M1T01+ ξcC −
ζ2M2T0
1+ ξcC
− ϕ2CT0
1+ ξ2M2
− µ0T0,
dT1
dt
=
ξd M1T0
1+ ξcC
+
ρ3T1C
η + C
+
ε1T1C
1+ ξ2M2
− β1T1C− µ1T1,
dT2
dt
=
ζ2M2T0
1+ ξcC
+
ρ4T2C
η + C
+
(ε4T2 + ε5M2)C
1+ ξiT1
− µ2T2,
dT17
dt
=
ϕ2CT0
1+ ξ2M2
+
ρ5T17C
η + C
+ (e7T17 + ecC)C− µ17T17,
dT8
dt
= ωM1D + σ8 +
ρtT8C
η + C
+
(ε8T1 + ε9T17)C
1+ ξcC + ξ2M2
− β8T8C− µ8T8,
dC
dt
= θ1C(1− θ2C) + αm M2 −Φ (M1 + N + T8)C− εpT1C,
(3.2.1)
where κ = α1νγδs , λ =
τ(ν4+ν13)
δp
, ϕ1 =
τ(ν6+νβ)
δp
, ξt =
µeνγ
δs
, ε1 =
γ1ν2
δs
, ξc =
hβνβ
δp
, ε2 =
γ2ν12
δs
,
ε7 =
γ2ν17
δs
, ξ2 = h10ν10δp , ω =
αtν12
δs
, ξd =
ζ1ν12
δs
, ϕ2 =
ζ3(ν6+νβ)
δp
, ε4 =
γ3ν4
δp
, ε5 =
γ3ν10
δp
, ξi =
hγνγ
δs
,
e7 =
γ4ν21
δs
+ γ4ν23δp , ec =
γ4νc
δp
, ε8 =
γ5ν2
δs
, ε9 =
γ5ν17
δs
, and εp =
µcνα
δs
with general initial
conditions M0(0) = M00, M1(0) = M
0
1, M2(0) = 0, N(0) = N
0, D(0) = D0, T0(0) = T00 ,
T1(0) = 0, T2(0) = 0, T17(0) = 0, T8(0) = T08 , and C(0) = C
0.
3.3 Model Analysis
In this section, we shall state some properties which guarantee the existence of non-
negative solutions for our model as we are dealing with cell populations and only such
solutions will be biologically meaningful.
Theorem 3.3.1 (Picard Lindelöf theorem). Consider the IVP,
y′(t) = f (t, y(t)), y(t0) = y0, t ∈ [t0 − e, t0 + e] .
Suppose f is Lipschitz continuous in y and continuous in t. Then, for some value e > 0, there
exist a unique solution y(t) to the IVP within the range [t0 − e, t0 + e] [93].
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Theorem 3.3.2. Let us denote y = (yi)i=1,..,n and consider the function f : R+ ×Rn+ → Rn
continuous with respect to (t, y) and Lipschitz continuous with respect to y. If fi(t, y) ≥ 0 for
(t, y) ∈ R+×Rn, with yi = 0 then for every y0 ∈ Rn+ there exists T > 0 such that the solution
to (3.2.1) exists on some interval [0, T), is unique and positive. If T < ∞, then
lim sup
t→T
n
∑
i=1
yi = +∞,
[93].
Theorem 3.3.3. For the initial condition
(
M00, M
0
1, M
0
2, N
0, D0, T00 , T
0
1 , T
0
2 , T
0
17, T
0
8 , C
0) ∈ R11+
at t0 = 0 the solution to (3.2.1) exists, is unique and non-negative on R+.
Proof. Let us consider model (3.2.1) and denote
f1 (X) = m− κM0T1 − α2M0C− δ0M0,
f2 (X) = κM0T1 +
ρ1M1C
η + C
− (λT2 + ϕ1C)M1 − δ1M1,
f3 (X) = α2M0C + (λT2 + ϕ1C)M1 − ξtT1M2 − δ2M2,
f4 (X) = n +
ρnNC
η + C
+
ε1T1C
1+ ξcC
− βnNC− δnN,
f5 (X) = d +
ρdDC
η + C
+
(ε2M1 + ε7T17)C
1+ ξcC + ξ2M2
− δdD,
f6 (X) = ωM1D + σ0 − ξd M1T01+ ξcC −
ζ2M2T0
1+ ξcC
− ϕ2CT0
1+ ξ2M2
− µ0T0,
f7 (X) =
ξd M1T0
1+ ξcC
+
ρ3T1C
η + C
+
ε1T1C
1+ ξ2M2
− β1T1C− µ1T1,
f8 (X) =
ζ2M2T0
1+ ξcC
+
ρ4T2C
η + C
+
(ε4T2 + ε5M2)C
1+ ξiT1
− µ2T2,
f9 (X) =
ϕ2CT0
1+ ξ2M2
+
ρ5T17C
η + C
+ (e7T17 + ecC)C− µ17T17,
f10 (X) = ωM1D + σ8 +
ρtT8C
η + C
+
(ε8T1 + ε9T17)C
1+ ξcC + ξ2M2
− β8T8C− µ8T8,
f11 (X) = θ1C(1− θ2C) + αm M2 −Φ (M1 + N + T8)C− εpT1C,
with f = ( f1, f2, f3, f4, f5, f6, f7, f8, f9, f10, f11), X = (M0, M1, M2, N, D, T0, T1, T2, T17, T8, C) ,
and X0 =
(
M00, M
0
1, M
0
2, N
0, D0, T00 , T
0
1 , T
0
2 , T
0
17, T
0
8 , C
0) .
Existence and uniqueness of the solution. It can be noticed that the function f is
continuous and Lipschitz continuous with respect to X. According to the Picard the-
orem, Theorem 3.3.1, there exists τ0 > 0 such that the solution to (3.2.1) exists and is
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defined locally at least on [0, τ0]. Again, let us consider the initial condition X1 = X(τ0)
at t0 = τ0. Using Theorem 3.3.1, it follows that there exist τ0 ≤ τ1 ∈ R+ and a unique
solution to (3.2.1) defined on [τ0, τ1]. By uniqueness of the solution of (3.2.1) with a given
initial condition, it follows that the solutions of (3.2.1), obtained on [0, τ0] and on [τ0, τ1]
form a unique solution of (3.2.1) on [0, τ1] with the initial condition X0 at t0 = 0. Re-
peating this process infinitely many times, we obtain the maximal forward interval of a
existence for the solutions of (3.2.1), [0,+∞).
Positivity of the solution. For X ∈ R11+ ,
f1 (0, M1, M2, N, D, T0, T1, T2, T17, T8, C) ≥ 0,
f2 (M0, 0, M2, N, D, T0, T1, T2, T17, T8, C) ≥ 0,
f3 (M0, M1, 0, N, D, T0, T1, T2, T17, T8, C) ≥ 0,
f4 (M0, M1, M2, 0, D, T0, T1, T2, T17, T8, C) ≥ 0,
f5 (M0, M1, M2, N, 0, T0, T1, T2, T17, T8, C) ≥ 0,
f6 (M0, M1, M2, N, D, 0, T1, T2, T17, T8, C) ≥ 0,
f7 (M0, M1, M2, N, D, T0, 0, T2, T17, T8, C) ≥ 0,
f8 (M0, M1, M2, N, D, T0, T1, 0, T17, T8, C) ≥ 0,
f9 (M0, M1, M2, N, D, T0, T1, T2, 0, T8, C) ≥ 0,
f10 (M0, M1, M2, N, D, T0, T1, T2, T17, 0, C) ≥ 0,
f11 (M0, M1, M2, N, D, T0, T1, T2, T17, T8, 0) ≥ 0
Therefore, according to Theorem 3.3.2, the unique solution of (3.2.1) is positive on [0,+∞).
This suggests that, for any initial condition inR11+ , the problem (3.2.1) possesses a unique
and positive solution in R11+ .
3.3.1 Equilibrium Points and Basic Reproduction Number
Definition 3.3.4. A point v∗ ∈ R is called an equilibrium point of v′ = f (v) if f (v∗) = 0.
The equilibrium point of the system (3.2.1) is calculated by equating the time rate of
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Modelling TME Components Dynamics 32
change of the equation to zero. Hence system (3.2.1) becomes,
m− κM∗0 T∗1 − α2M∗0C∗ − δ0M∗0 = 0
κM∗0 T∗1 +
ρ1M∗1C
∗
η + C∗
− (λT∗2 + ϕ1C∗)M∗1 − δ1M∗1 = 0
α2M∗0C∗ + (λT∗2 + ϕ1C∗)M∗1 − ξtT∗1 M∗2 − δ2M∗2 = 0
n +
ρnN∗C∗
η + C∗
+
ε1T∗1 C
∗
1+ ξcC∗
− βnN∗C∗ − δnN∗ = 0
d +
ρdD∗C∗
η + C∗
+
(ε2M∗1 + ε7T
∗
17)C
∗
1+ ξcC∗ + ξ2M∗2
− δdD∗ = 0
ωM∗1 D
∗ + σ0 − ξd M
∗
1 T
∗
0
1+ ξcC∗
− ζ2M
∗
2 T
∗
0
1+ ξcC∗
− ϕ2C
∗T∗0
1+ ξ2M∗2
− µ0T∗0 = 0
ξd M∗1 T
∗
0
1+ ξcC∗
+
ρ3T∗1 C
∗
η + C∗
+
ε1T∗1 C
∗
1+ ξ2M∗2
− β1T∗1 C∗ − µ1T∗1 = 0
ζ2M∗2 T∗0
1+ ξcC∗
+
ρ4T∗2 C∗
η + C∗
+
(ε4T∗2 + ε5M∗2)C∗
1+ ξiT∗1
− µ2T∗2 = 0
ϕ2C∗T∗0
1+ ξ2M∗2
+
ρ5T∗17C
∗
η + C∗
+ (e7T∗17 + ecC
∗)C∗ − µ17T∗17 = 0
ωM∗1 D
∗ + σ8 +
ρtT∗8 C∗
η + C∗
+
(ε8T∗1 + ε9T
∗
17)C
∗
1+ ξcC∗ + ξ2M∗2
− β8T∗8 C∗ − µ8T∗8 = 0
θ1C∗(1− θ2C∗) + αm M∗2 −Φ (M∗1 + N∗ + T∗8 )C∗ − εpT∗1 C∗ = 0
(3.3.1)
We proceed by classifying and analysing the equilibrium points of system (3.3.1) as
follows:
3.3.1.1 The tumor free equilibrium (TFE)
As the name implies, the tumor free equilibrium illustrates the equilibrium state whereby
the system is free from the disease. In order to calculate the TFE, we set all the infectious
compartment to zero. It follows that, in the case of our model, the compartment for
tumor cells (C) and the anti-inflammatory macrophages (M2) will be set to zero. That
is, C(t) = M2(t) = 0. Hence, solving system (3.3.1), the tumor free equilibrium point
E0 = (M∗0 , M∗1 , M
∗
2 , N
∗, D∗, T∗0 , T∗1 , T
∗
2 , T
∗
17, T
∗
8 , C
∗) is given by:
E0 =
(
m
δ0
, 0, 0,
n
δn
,
d
δd
,
σ0
µ0
, 0, 0, 0,
σ8
µ8
, 0
)
.
3.3.1.2 The endemic equilibrium
The endemic equilibrium point is the state where the tumor cells cannot be totally erad-
icated but remain in the population of the tumor microenvironment. The endemic equi-
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librium point is solved using Maple software which confirms the existence of some posi-
tive cancer persistence equilibrium points. Due to the complexity of the results derived,
we, therefore, do not state the solutions of the state variables. We shall, therefore, pro-
ceed to determine the threshold parameter. That is the basic reproductive number (R0)
for our model which shall further be used for analysing the local and global stability of
the tumor free equilibrium point of the model.
3.3.1.3 The basic reproduction number
The basic reproductive numberR0 can be defined as the number of new infections pro-
duced by an infective individual (tumor cell) in a population at a disease free equilib-
rium [110]. In the case of this study, the basic reproductive number can be defined as
the number of immune-cancerous cells caused by a tumor cell as a result of the local in-
teraction between the immune cells and tumor cells in the tumor microenvironment at a
tumor free equilibrium. Using next generation matrix, computingR0 requires us to first
distinguish new infections from every other change in the cell population as explained
below.
• Let Fi(x) be the rate at which a new infection appears in ith compartment.
• V+i (x) be the rate at which individuals are transferred into compartment i by other
means, and
• V−i (x) be the transfer rate of individuals out of the ith compartment
We can therefore express the infectious compartment model in the form
dxi
dt
= Fi(x)− Vi(x),
where Vi(x) = V−i (x)− V+i (x), x ∈ R11+ , and i = 1, 2, . . . , m is the number of infectious
compartment. Each function is assumed to be continuously differentiable at least twice
in each variable [110]. Evaluating at the TFE E0, we then have,
F =
[
∂Fi
∂xj
(E0)
]
and V =
[
∂Vi
∂xj
(E0)
]
with i ≤ 1 and j ≤ m such that R0 is the maximum eigenvalue of the matrix formed
from FV−1
In the case of our model, as stated earlier the disease compartments are the anti-
inflammatory (M2) macrophages M2 and tumor cells C, therefore the equation for the
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infectious compartment model is given by
dM2
dt
= α2M0C + (λT2 + ϕ1C)M1 − ξtT1M2 − δ2M2
dC
dt
= θ1C(1− θ2C) + αm M2 −Φ (M1 + N + T8)C− εpT1C
which implies that
Fi =
F1
F2
 =
α2M0C + ϕ1M1C
0
 .
and
Vi =
V1
V2
 =
 ξtT1M2 + δ2M2 − λT2M1
θ1θ2C2 +Φ (M1 + N + T8)C + εpT1C− αm M2 − θ1C
 .
Hence linearizing Fi and Vi at the tumor free equilibrium E0 gives,
F =

∂F1(E0)
∂M2
∂F1(E0)
∂C
∂F2(E0)
∂M2
∂F2(E0)
∂C
 = ( 0 α2mδ0
0 0
)
,
and
V =

∂V1(E0)
∂M2
∂V1(E0)
∂C
∂V2(E0)
∂M2
∂V2(E0)
∂C
 = ( δ2 0−αm Φ( nδn + σ8µ8)− θ1
)
.
Since V is a non-singular matrix, we therefore obtain its inverse to be,
V−1 =
 1δ2 0αm(
Φ
(
n
δn +
σ8
µ8
)
−θ1
)
δ2
1
Φ
(
n
δn +
σ8
µ8
)
−θ1
 .
Hence, the next generation matrix is given by
FV−1 =
 α2αmm(Φ( nδn + σ8µ8 )−θ1)δ0δ2 α2m(Φ( nδn + σ8µ8 )−θ1)δ0
0 0
 . (3.3.2)
Thus the eigenvalues for the above matrix in Equation (3.3.2) are
λ1 =
α2αmm(
Φ
(
n
δn
+ σ8µ8
)
− θ1
)
δ0δ2
, λ2 = 0
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Therefore the basic reproductive number is,
R0 = α2αmm(
Φ
(
n
δn
+ σ8µ8
)
− θ1
)
δ0δ2
, (3.3.3)
with Φ
(
n
δn
+ σ8µ8
)
> θ1.
3.3.2 Stability Analysis of the Equilibrium Points
3.3.2.1 Local Stability of the tumor free Equilibrium
Theorem 3.3.5 (Geshgorin’s Theorem). Let B = (bij)1≤i,j≤n be an n× n matrix and Di be
the disk in the complex plane with center at bii and radius ri = ∑nj=1,j 6=i |bij|, then all eigenvalues
of the matrix B lie in the union of the disk Di. In particular, if λ is an eigenvalue of B, then for
some i = 1, 2, . . . , n, |λ− bii| ≤ ri [1].
Corollary 3.3.6. Let B = (bij)1≤i,j≤n be an n × n matrix with real entries. If the diagonal
elements of B satisfies bii < −ri where ri = ∑nj=1,j 6=i |bij| for i = 1, 2, . . . , n, then the eigenvalues
of B are negative. i.e. the matrix has negative real parts [1].
Theorem 3.3.7. The tumor free equilibrium E0 of our model (3.2.1) is locally asymptotically
stable ifR0 < 1. [110].
Proof. The Jacobian matrix evaluated at the tumor free equilibrium E0 is given below as
J(E0) =

−δ0 0 0 0 0 0 − κmδ0 0 0 0 −
α2m
δ0
0 −δ1 0 0 0 0 κmδ0 0 0 0 0
0 0 −δ2 0 0 0 0 0 0 0 α2mδ0
0 0 0 −δn 0 0 0 0 0 0 B
0 0 0 0 −δd 0 0 0 0 0 ρddηδd
0 E − ζ2σ0µ0 0 0 −µ0 0 0 0 0 −
ϕ2σ0
µ0
0 ξdσ0µ0 0 0 0 0 −µ1 0 0 0 0
0 0 ζ2σ0µ0 0 0 0 0 −µ2 0 0 0
0 0 0 0 0 0 0 0 −µ17 0 ϕ2σ0µ0
0 ωdδd 0 0 0 0 0 0 0 −µ8 M
0 0 αm 0 0 0 0 0 0 0 −N

(3.3.4)
where,
B =
n
δn
(
ρn
η
− βn
)
, E =
ωd
δd
− ξdσ0
µ0
, M =
σ8
µ8
(
ρt
η
− β8
)
, N = Φ
(
n
δn
+
σ8
µ8
)
− θ1.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Modelling TME Components Dynamics 36
Since our Jacobian matrix has real entries, it follows from Corollary 3.3.6, that the
eigenvalues of Jacobian matrix (3.3.4) has negative real part under the conditions:

δ0 >
m
δ0
(κ + α2) ,
δ1 >
κm
δ0
,
δ2 >
α2m
δ0
,
δn >
n
δn
(
βn − ρnη
)
,
δd >
ρdd
ηδd
,
µ0 >
σ0
µ0
(ξd + ζ2 + ϕ2)− ωdδd ,
µ1 >
ξdσ0
µ0
,
µ2 >
ζ2σ0
µ0
,
µ17 >
ϕ2σ0
µ0
,
µ8 >
ωd
δd
+ σ8µ8
(
β8 − ρtη
)
,
Φ
(
n
δn
+
σ8
µ8
)
− θ1 > αm .
Let us show that at the tumor free equilibrium, R0 < 1. By multiplying the boxed
conditions which corresponds to the disease transmission model, we obtain[
Φ
(
n
δn
+
σ8
µ8
)
− θ1
]
δ2 >
α2αmm
δ0
. (3.3.5)
Multiplying Equation (3.3.5) by δ0, gives[
Φ
(
n
δn
+
σ8
µ8
)
− θ1
]
δ0δ2 > α2αmm. (3.3.6)
Furthermore, dividing Equation (3.3.6) by its left hand side gives
1 >
α2αmm[
Φ
(
n
δn
+ σ8µ8
)
− θ1
]
δ0δ2
= R0,
∴ R0 < 1.
(3.3.7)
We conclude that the tumor free equilibrium point E0 is locally asymptotically stable.
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3.3.2.2 Global Stability of the tumor free Equilibrium
In the previous section, we were able to show the local stability of TFE for R0 < 1.
We will now proceed to employ the following theorem used by [19], which guarantees
global stability of the tumor free equilibrium point whenR0 < 1.
Theorem 3.3.8. The disease free equilibrium point E0 is globally asymptotically stable provided
thatR0 < 1 and the following conditions are satisfied. That is,
If the system is re-written in the form
dX
dt
= F(X, Y)
dY
dt
= G(X, Y) with G(X, 0) = 0,
where X ∈ Rn components depict the number of uninfected individuals and where Y ∈ Rm com-
ponents depict the number of infected individuals within the system and the following conditions
are met:
1. For dXdt = F(X, 0), E0 is globally asymptotically stable, and
2. Gˆ(X, Y) = AY − G(X, Y) > 0 for (X, Y) ∈ Ω the feasibility region, where A is the
Jacobian matrix formed at the disease free equilibrium [19].
Therefore, applying Theorem 3.3.8 for global stability, system (3.2.1) can be re-written in
the form
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Modelling TME Components Dynamics 38
dX
dt
= F(X, 0) =

m− κM0T1 − δ0M0
κM0T1 − λT2M1 − δ1M1
n− δnN
d− δdD
ωM1D + σ0 − ξd M1T0 − µ0T0
ξd M1T0 − µ1T1
−µ2T2
−µ17T17
ωM1D + σ8 − µ8T8

dY
dt
= G(X, Y) =
 α2M0C + (λT2 + ϕ1C)M1 − ξtT1M2 − δ2M2
θ1C(1− θ2C) + αm M2 −Φ (M1 + N + T8)C− εpT1C

where X = [M0, M1, N, D, T0, T1, T2, T17, T8]
T and Y = [M2, C]
T .
Therefore,
A =

−δ2 α2mδ0
αm θ1 −Φ
(
n
δn
+ σ8µ8
)
 ,
such that
AY =

−δ2 α2mδ0
αm θ1 −Φ
(
n
δn
+ σ8µ8
)

M2
C

=

−δ2M2 + α2mδ0 C
αm M2 + θ1C−Φ
(
n
δn
+ σ8µ8
)
C
 .
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From condition 2.
Gˆ(X, Y) = AY− G(X, Y)
⇒ Gˆ(X, Y) =
−(λT2 + ϕ1C)M1 + ξtT1M2
θ1θ2C2 +ΦM1C + εpT1C
 =
Gˆ1(X, Y)
Gˆ2(X, Y)

From the above expression, it is obvious that Gˆ2(X, Y) = θ1θ2C2 +ΦM1C+ εpT1C ≥
0 since all parameters used in the model are assumed to be non-negative. However,
according to Theorem 3.3.8, for the tumor free equilibrium, E0, to be globally asymp-
totically stable, Gˆ(X, Y) must be greater than or equal zero. It follows that Gˆ1(X, Y)
must also be greater or equal to zero. Thus, Gˆ1(X, Y) ≥ 0 if and only if ξtT1M2 ≥
(λT2 + ϕ1C)M1. Therefore the tumor free equilibrium, E0, will be globally asymptot-
ically stable if the elimination rate of M2 macrophages by Th1 cells is more than the
transition of M1 macrophages to M2 macrophages caused by both Th2 cells and tumor
cells.
3.4 Numerical Analysis
3.4.1 Parameter Estimation
For system (3.2.1), about 62.2% of the parameters are gotten from literature related to
our work, and we use the non-linear least square method, which was proposed by John
Nelder and Roger Mead [79], to estimate the unknown parameter values of the model.
Graphical representations of the observed data estimates are also depicted.
3.4.1.1 Non-linear Least Square (NLS) Method
Let us consider the following initial value problem
d
dt
y(t, θ) = f (t, y, θ)
y(0, θ) = y0,
(3.4.1)
where the function f depends on time t, y is the state variable and the vector of param-
eters θ is to be estimated. The procedure used by the least square method for estimating
parameters is to minimize the sum of the difference between observed data points, y(ti),
and the solution of the model, yˆ(ti, θ), associated with the model parameter θ. Mathe-
matically, given n data points, (ti, yi) for i = 1, . . . , n, we seek to minimize the error by
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the given function,
M(θ) =
n
∑
i=1
[yˆ(ti, θ)− y(ti)]2 . (3.4.2)
Therefore, finding the parameters vector θ = (θi)0≤i≤m that best fit our model implies
solving the following optimization problem
min
θ
M(θ) subject to θmin ≤ θi ≤ θmax, (3.4.3)
for i = 1, . . . , m, where m is the number of parameters to be estimated.
3.4.1.2 Estimated Values and Fitted Plot
We implemented our model using the deSolve package in R, and fitted the model to
real data using optim in R. This was done using the non-linear least square (NLS) as
explained above. Figure 3.2 shows the suitable curve fitting together with the estimated
values to unknown parameters of the model. We fitted our model to observed real data
of tumor cells growth used by [26]. The estimated values of the unknown parameters
obtained from the non-linear least square method and literature are recorded in Table
3.3. These parameter values will therefore be used for our analysis.
3.4.2 Numerical Simulation
The numerical simulation of our model equation (3.2.1) is done using deSolve pack-
age in R software. In these simulations, the initial concentration of the immune system
cells used are, resting macrophages, M0(0) = 4× 105 cells/ml; activated macrophages,
M1(0) = 8× 103 cells/ml [4]; Nk cells, N(0) = 3.2× 103 cells/ml [69]; dendritic cells,
D(0) = 103 cells/ml [41]; CD8+ T cells, T8(0) = 7.15× 103 cells/ml [27]; naive CD4+
T cells, T0(0) = 5× 103 cells/ml; the initial concentration of every other cells is zero as
explained in equation (3.2.1); and the that of tumor cells, C(0) = 6.9× 104 cells/ml as
recorded in [26]. All other parameters used, are stated in Table 3.3.
Figure 3.3 depicts the tumor-immune cell dynamics of our model equation (3.2.1). It
suggests that with the parameter estimation and values used in the model, in a biologi-
cal time frame, our model can produce tumor escape from immunological surveillance
in the tumor microenvironment. This shows the capacity of a tumor to escape from im-
munological surveillance when the immune system cells are depleted at tumor site [69].
This might be because, from our parameter values, the inactivation rate for the two pri-
mary immune-effector cells (the NK cells and CD8+ T cells) by tumor cells are assumed
to be 1 per cell per day [50, 54]. It follows that there are few cytotoxic immune-effector
cells or weak immune system cells at the tumor site.
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Figure 3.2: Plot showing curve fitting of tumor cell populations of model (3.2.1) to real
data of tumor growth.
In order to understand further how the whole immune cells interact in this scenario,
let us proceed by taking into consideration related parameter values to the inactivate
rate of NK cells and CD8+ T cells due to tumor cells used by [29] and [28], respectively.
That is, βn = 3.5× 10−6 and β8 = 1× 10−7 in our model which implies that there are
more immune-effector cells or strong immune system cells at the tumor site. Thus, it
depicts high effectiveness of immunological surveillance mediated by both Nk cells and
activated CD8+ T cells as it shows their capability of controlling tumor growth. The
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Table 3.3: Description, units and source of parameter values used in the model
Parameter Description Value Units Source
d External influx rate of DCs 4.8× 102 cells/ml/day [108]
m External influx rate of macrophages 2.28× 102 cells/ml/day [67]
n External influx rate of NK cells 3.2× 103 cells/ml/day [69]
σ0 Constant supply of Th0 cells upon activation 0.7336828 cells/ml/day Estimated
σ8 Constant supply of CD8+ T cells upon activation 1.0× 102 cells/ml/day [27]
ρ1 Proliferation rate of M1 Macrophages 0.995 day−1 Estimated
ρ3 Proliferation rate of Th1 cell 0.6156879 day−1 Estimated
ρ4 Proliferation rate of Th2 cell 0.0000001 day−1 Estimated
ρ5 Proliferation rate of Th17 cell 0.2032233 day−1 Estimated
ρn Proliferation rate of NK cells 0.120393 day−1 Estimated
ρd Proliferation rate of DCs 0.00000029 day−1 Estimated
ρt Proliferation rate of CD8+ T cells 0.4487595 day−1 Estimated
η Half saturation constant of the immune response 1.0× 103 [34]
τ Transition rate from M1 to M2 Macrophages by anti-inflammatory cytokines 0.2 day−1 [67]
βn Inactivation rate of NK cells by tumor cells 1 day−1 cell−1 [50],[54]
β1 Inactivation rate of Th1 cells by tumor cells 0.995 day−1 cell−1 Estimated
β8 Inactivation rate of CD8+ T cells by tumor cells 1 day−1 cell−1 [50],[54]
θ1 Intrinsic growth rate of tumor cells 0.3655 day−1 Average([27],[36])
θ2 Maximum carrying capacity of tumor cells 2.17× 10−8 cell−1 [27]
αm Expansion rate of tumor cells by M2 macrophages 0.0000001 day−1 Estimated
γ1 Expansion rate of NK and Th1 cells enhanced by IL-2 0.1245 day−1 [36],[54]
γ2 Expansion rate of dendritic cells enhanced by IL-12 and IL-17 0.8025290 day−1 Estimated
γ3 Expansion rate of Th2 cells enhanced by IL-4 and IL-10 0.0000001 day−1 Estimated
γ4 Expansion rate of Th17 cells enhanced by IL-21 and IL-23 0.0000001 day−1 Estimated
γ5 Expansion rate of CD8+ T cells by enhanced IL-2 and IL-17 0.1245 day−1 [54]
α1 Polarization of resting macrophages into M1 0.7877726 cells/ml/day Estimated
α2 Polarization of resting macrophages into M2 0.4335230 cells/ml/day Estimated
αt Activation rate of T cells 8.0× 10−3 cells/ml/day [34]
ζ ′is Th0 differentiation into it subsets 5.5× 10−1 cells/ml/day [34]
δ′i s Apoptosis rate of macrophage phenotypes 2.0× 10−2 day−1 [67]
δn Apoptosis rate of NK cells 4.12× 10−2 day−1 [27],[69]
δd Apoptosis rate of DCs 2.4× 10−2 day−1 [108]
µ′is Apoptosis rate of Th0 cell and its subsets 0.05 day
−1 [28]
µ8 Apoptosis rate of CD8+ T cells 2.0× 10−2 day−1 [27],[69]
Φ Elimination rate of tumor cells by immune effector cells 1.0× 10−5 day−1 [28]
µc Apoptosis rate of tumor cells by TNF-α 0.2 day−1 [34]
µe Apoptosis rate of M2 macrophages by IFN-γ 0.9398057 day−1 Estimated
hγ Inhibition measure by IFN-γ 0.02235745 day−1 Estimated
hβ Inhibition measure by TGF-β 1.0× 10−3 day−1 [50]
h10 Inhibition measure by IL-10 2.0× 10−7 day−1 [41]
ν′i s Production rate of tumor suppressing cytokines by immune cells 3.72× 10−5 pg/cell/day [63]
ν′js Production rate of tumor promoting cytokines by immune cells 1.5× 10−5 pg/cell/day [63]
ν′ks Production rate of tumor promoting cytokines by tumor cells 7.5× 10−4 pg/cell/day [4]
δs Decay rate of tumor suppressing cytokines 10 day−1 [27],[34],[54]
δp Decay rate of tumor promoting cytokines 34 day−1 [34]
results are presented in Figure 3.4, 3.5 and 3.6.
Figure 3.4 and 3.5 give a clear picture of the effects on each of the respective immune
cells used in the model in both cases of when there are weak and strong immune ef-
fector cells in the tumor microenvironment. Figure 3.4(a) and 3.5(a) is the case where
there are weak immune effector cells at the tumor site. It results in tumor promoting
immune cells (M2 macrophages, Th2 cells and Th17 cells) evading the system thereby
contributing to tumor growth progression as depicted in Figure 3.5(a). On the other
hand, the tumor suppressing/cytotoxic immune cells (M1 macrophages, Nk cells, Th1
cells and CD8+ T cells) go into extinction as shown in Figure 3.4(a). Meanwhile, in the
case whereby strong immune effector cell is present at the tumor site, as shown in Figure
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Figure 3.3: Plot showing the growth of tumor and immune cell populations over time.
The plot indicates tumor escape of immunological surveillance due to weak immune
effector cell.
3.4(b) and 3.5(b), an increase in the the tumor suppressing/cytotoxic immune cell (M1
macrophages, Nk cells and CD8+ T cells) densities lead to the inhibition/decrease of
the population of tumor promoting immune cells (M2 macrophages, Th2 cells and Th17
cells) in the system. However M2 macrophages still dominate at some point in time in
the system. This is expected to happen because those macrophages that undergo the
process of phagocytosis need to be depleted from the system and it will certainly be a
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Figure 3.4: Plot shows tumor suppressing immune cell populations over time when: (a)
there is a weak immune effector cell at tumor site, and (b) there is a strong immune
effector cell at tumor site
gradual process for that to happen.
Figure 3.6 shows the tumor-immune cells dynamics of our model over a period of
40 days to 300 days with βn = 3.5× 10−6 and β8 = 1× 10−7. From Figure 3.6 (a), we
observed a declined growth of the tumor cells to a dormant stage. However, in Figure
3.6 (b) our model predicts the total extinction of the tumor cells in the system. In the
long run (starting roughly from a period of 200 days onward) the immune system will
be in place leaving out the innate immune system to perform its first line of defence.
3.4.3 Sensitivity Analysis
It is expected that assumptions made on our model and estimated parameter values
might be subject to slight changes or errors. As a result, we proceed by carrying out
a sensitivity analysis of the model output to all estimated parameters and key model
parameters as presented in Figure 3.7. Using function sensFun in FME package in R [99],
we investigated how alterations in such parameters influence the model output. As
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Figure 3.5: Plot shows tumor promoting immune cell populations over time when: (a)
there is a weak immune effector cell at tumor site, and (b) there is a strong immune
effector cell at tumor site
shown in Figure 3.7, parameters γ3,γ4, ρd, µe, hγ, ρ3, ρ4, µ1, and αm do not have an effect
on the number of tumor cell load while parameter Φ has a consistent negative effect on
the number of tumor cell load (see Figure 3.7 (e)). This was expected because Φ is the
eliminate rate of tumor cells by immune-effector cells while other parameters such as
σ0, n, α2,γ2, θ1, ρt, β1, α1, m, d, σ8, βn, β8, ρ1, αt, δ0, δ2, ρn, δn, µ0, µ2, µ8, µ17, µc and τ have an
inconsistent effect, either positive or negative, with time. This might be caused by the
strength of their respective immune effector cells in that interval of time at the tumor site.
To investigate how specific some of these parameters influence our model behaviour, we
proceed by performing a local sensitivity analysis on some key parameters of interest.
Figure 3.8 shows the dynamic of the tumor cells with time by varying some key
parameters in the model. In Figure 3.8 (a), we varied the intrinsic growth rate, θ1, of tu-
mor cell. As expected in the numerical solution, an increase in this growth rate leads to a
rapid increase in the growth of tumor cell thereby increasing the time evolution of tumor
cells in the tumor microenvironment and vice versa. Similarly Figure 3.8 (b) shows effect
of varying parameter αm. It depicts the fact that tumor associated macrophages (TAMs)
promote tumor growth and progression before it is eliminated from the system. Also,
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(a) (b)
Figure 3.6: Plot showing the growth of tumor and immune cell populations over time.
The plot indicates tumor elimination due to strong immune effector cell at βn = 3.5×
10−6 and β8 = 1× 10−7 (a) over a period of 40 days and (b) over a period of 300 days.
it was observed that an increase in the number of αm contributes towards the growth of
tumor cells in the tumor microenvironment. On the other hand, Figure 3.8 (c) and (d)
show the effect of varying parameter ρ1 and Φ, respectively. Figure 3.8 (c) presents the
proliferation rate of activated macrophages due to stimulus from tumor cells thereby
engulfing and preparing them for death, while Figure 3.8 (d) shows the elimination rate
of tumor cells by immune-effector cells. It was observed that an increase in the rate of
these parameters does not only reduce the tumor cell populations but also decrease the
time evolution of tumor cells in the tumor microenvironment.
Figure 3.8 (e) and (f), depict the effect of varying parameter βn and β8, that is, the
inactivation rate of NK cell and CD8+ T cells respectively by tumor cells. It was observed
that a decrease in the inactivation rate of these cells lead to a decrease in the tumor cell
population and delayed tumor growth. In order words, the immune effector cells are
more active/stronger in carrying out tumor lysis. Also, we observed from 3.8 (f) that a
decrease in β8 not only leads to the reduction of the tumor cell population but also to a
gradual elimination of the tumor cells in the tumor microenvironment.
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3.4.4 Effect of Cytokine Concentration in the TME
In the case of our model, the concentrations of both tumor promoting cytokines (IL-4, IL-
6, IL-10, IL-13, IL-23, and TGF-β) and tumor suppressing cytokines (IL-12, IL-17, IL-21,
TNF-α, and IFN-γ) with respect to time are shown in Figure 3.9 and Figure 3.10. Fig-
ure 3.9 is the case where we have weak immune effector cells as explained above. We see
that the tumor promoting cytokines start manifesting roughly from Day 10 which cor-
relate to when there is an increase in tumor growth population as shown in Figure 3.3.
Also, we observed a continuous increment in the concentration of these cytokines. At
Day 40, in Figure 3.9(b), we observed that the concentration of cytokine IL-23 is higher
compared to other tumor promoting cytokines in the TME. This may be the reason why
the innate immune system are being stopped by IL-23 produced by the tumor cell in
the tumor micro-environment [105], and also leads to it inducing immunosuppression
through down-regulation of CD4+ and CD8+ T cells infiltrating in tumor tissues as re-
ported by [80] thereby leading to tumor progression. However, the depletion of the
tumor suppressing cytokines leads to a decrease in the population, efficiency and the
cytotoxic effect of the immune effector cells. While in Figure 3.10 we observe that the
concentration of IL-23 is minimal when the immune effector cells are strong in the tumor
microenvironment which bring about the elimination of the tumor cells. This supports
the idea from previous research that tumor promoting cytokine IL-23 plays a signifi-
cant role in the growth and proliferation of tumor. Its antibody can therefore be used to
achieve an increased tumor eradication or a delayed tumor growth.
In conclusion from the simulation of our model, we predicted that few immune-
effector cells at the tumor site led to tumor escape while high immune-effector cells at
the tumor site led to tumor regression. Among others, cytokine IL-10, IL-23, TNF-α,
TGB-β and IFN-γ are also identified to play a significant role in our model based on
the observed dynamics in the level of their concentration in the system. We, therefore,
conclude that the availability of these cytokines in the system has a great effect on the
host immune cells response and hence in the tumor microenvironment. Thus in the
next chapter, we shall identify proteins(breast cancer genes) that regulates these key
cytokines in our model and possibly suggest essential proteins as a new development
for an effective treatment to eliminate breast cancer.
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Figure 3.7: Sensitivity functions of model output to parameters.
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(a) Plot shows the effect of varying the growth rate of
tumor cells θ1 in numerical solution of our model.
(b) Plot shows the effect of varying the expansion rate
of tumor cell by M2 macrophages αm in numerical
solution of our model.
(c) Plot shows the effect of varying the proliferation
rate of M1 macrophages ρ1 in numerical solution of
our model.
(d) Plot shows the effect of varying the elimination
rate of tumor cells by immune effector cells Φ in nu-
merical solution of our model.
(e) Plot shows the effect of varying the inactivation
rate of NK cells caused by tumor cells βn in numeri-
cal solution of our model.
(f) Plot shows the effect of varying the inactivation
rate of CD8+ T cells caused by tumor cells β8 in nu-
merical solution of our model.
Figure 3.8: Plot showing the effect of varying key parameters of interest in numerical
solution of our model. Other baseline parameter values used are as stated in Table 3.3.
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Figure 3.9: Plot indicates the concentration of pro-inflammatory cytokine (IL-12, IL-17,
IL-21, TNF-α, and IFN-γ) and anti-inflammatory cytokine (IL-4, IL-6, IL-10, IL-13, IL-23,
and TGF-β) when there are weak immune-effector cells at tumor site
Stellenbosch University  https://scholar.sun.ac.za
51 3.4. Numerical Analysis
Figure 3.10: Plot indicates the concentration of pro-inflammatory cytokine (IL-12, IL-17,
IL-21, TNF-α, and IFN-γ) and anti-inflammatory cytokine (IL-4, IL-6, IL-10, IL-13, IL-23,
and TGF-β) when there are strong immune-effector cells at tumor site
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Breast Cancer Drug Target
Identification
Breast cancer is a complex disease whereby some cells in the breast grow uncontrollably
to form a tumor. Sometimes, breast cancer is caused by abnormal genes passed from
parent to child which claimed approximately 5% to 10% of every occurrence of breast
cancer. Its prevalence in 2016 has been recorded globally to be the highest among other
cancer types [15]. Many research has been carried out on breast cancer [39, 73]. It has
been seen to pose a serious public health challenge thereby suggesting that to improve
the prevention of breast cancer development; we need to identify the environmental and
genetic factors that contribute to the development of breast cancer [39, 73]. This chapter
aims to identify breast cancer drug target. We proceed by first generating a unified hu-
man functional network using human protein sequences database gotten from different
biological data sources. We then characterize its protein-protein interaction networks
using network centrality measures. Finally, we identify proteins (breast cancer genes)
that triggers key cytokines in our model and suggest essential proteins as a new devel-
opment for an effective treatment to eliminate breast cancer (see Figure 4.1).
4.1 General View of the Unified Human Protein Functional
Network
In order to carry out the analysis of human protein-protein interaction networks, we
first generate a unified human protein functional network from different biological data
sources: Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database
(https://string-db.org/) and UniProt database (http://www.uniprot.org/). Protein
52
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Figure 4.1: Workflow of stepwise process from data integration to extraction of essential
drug target pathways for drug discovery in breast cancer.
sequence similarity is extracted by running sequence comparison tool: BLAST (Basic
Local Alignment Search Tool) on human protein sequence dataset downloaded from
UniProt database in Fasta format. We then proceded by extracting protein signature us-
ing InterPro signature data for Human proteins retrieved from the European Bioinfor-
matics Institute (EBI) at http://www.ebi.ac.uk/interpro/. Furthermore, we extracted
the interactions of this protein from STRING dataset.
Confidence scores defined by the STRING schemes are used with the functional
interaction derived from the STRING database. These confidence scores include con-
served genomic neighborhood, gene neighborhood transferred, gene fusion events, gene
co-occurrence or phylogenetic profile across multiple genomes, gene co-expression, gene
co-expression transferred, experiments, experiments transferred, text mining, text min-
ing transferred, and other databases. Additional interaction data derived from protein
sequence similarity and signatures are scored using an information-theoretic based ap-
proach which changes the shared biological content between proteins into confidence
score. For each evidence source, there are three categories of functional interaction
scores between proteins: low, medium and high confidence level. Low confidence inter-
actions level are said to have confidence score strictly less than 0.3, while the medium
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confidence level are interactions whose confidence score are between 0.3 and 0.7 in-
clusively (0.3 ≤ score ≤ 0.7) and any interactions whose confidence scores are strictly
greater than 0.7 (> 0.7) are categorized as high confidence level. Table 4.1 shows the
number of human protein-protein functional interaction in the networks and their con-
fidence scores.
Table 4.1: The number of human protein-protein functional interaction in the networks
and their confidence level
Association evidence by type Low confidence Medium confidence High confidence
STRING data 3585678 818652 311597
Sequence data 287997 359519 610485
Combined score 3759260 1159955 911474
For two proteins i and j the combined confidence score as shown in Table 4.1 is
computed by combining confidence scores between the proteins from all the datasets for
a unified network. Provided that the sources are independent, the combined confidence
score is given by
Cij = 1−
n
∏
s=1
(
1− csij
)
, (4.1.1)
where csij represents the confidence score between protein i and j using the source s in
the functional network [75, 76].
In order to minimize the effects of the computational and experimental predictions
bias, functional interactions ranging from medium to high confidence levels were con-
sidered alongside the functional interactions with low confidence which have been pre-
dicted by at least two approaches with a total number of 22,255 interactions. The sum-
mary of the general properties of the unified human protein functional interaction net-
work is given in Table 4.2. In the unified human protein functional interaction network,
we have in total 19,502 proteins (nodes) with 2,093,684 functional interactions (edges)
between proteins. It covers approximately 96% of the human proteome of which 1124
are structural hubs. That is proteins that are capable of disconnecting the network and de-
termine the level of integrity in the system. Communication of pairwise protein set over
a relative shortest connected path within the system is possible because of the presence
of these structural hubs.
Figure 4.2 represents the probability distribution of the shortest path length between
pair-wise protein in the unified human protein functional network. The average short-
est path length is derived by taking the mean of all shortest path between all pairs of
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Table 4.2: General properties of the unified human protein-protein functional network.
Parameters Value
Number of proteins (Nodes) 19502
Number of functional interactions (Edges) 2093684
Average shortest path length 2.63104
Average betweenness 51310.54
Average closeness 0.38008
Average degree 214.715
% of Nodes in largest component 96%
Number of hubs (key proteins) 1124
protein in the network. The biological information communication between a given
protein and other proteins within the network is done in just a few steps as the average
shortest length achieved is approximately 3. In other words, it shows how fast infor-
mation can be disseminated in the human protein functional network irrespective of the
number of proteins in the system. Another advantage regarding this property is that
the system would be able to effectively respond and quickly adjust to any change in the
environment [75].
We proceed by performing a degree distribution of the unified human functional
network. As illustrated in Figure 4.3, the system shows a scale-free topology, in the sense
that, there is an approximate power law P(k)=k−γ of degree distribution of proteins with
the degree exponent γ ∼ 1.32. This implies that the network has more proteins with
few interacting partners (low degree nodes) leaving just a few with many interacting
partners (high degree nodes). If the latter is removed from the network, it can disconnect
the network thereby affecting functions of the system. They are therefore considered to
be responsible for the completeness of the system thus essential for the survival of the
organism.
4.2 Genes Associated with Breast Cancer
Gene mutations are associated with most inherited cases of breast cancer. Breast cancer
gene one (BRCA1) and breast cancer gene two (BRCA2) are the two well-known suscep-
tibility genes causing cancer in the human breast. Normally, the functions of these breast
cancer genes are to repair DNA damages and to act as tumor suppressors by prevent-
ing cells from growing and metastasizing [123]. However, when mutations alter these
genes, it results in a higher risk of developing cancer. Depending on the population
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Figure 4.2: Shortest path length probability distribution between pair-wise node in the
human protein functional network.
under study, from previous research, a germline mutation in BRCA1 gene is known to
represent a predisposing genetic factor in about 15% to 45% of hereditary breast cancer
and at least 80% of breast and/or ovarian cancer. Whereas women with BRCA1 muta-
tion have about 60% to 80% likelihood of developing breast cancer [39, 73] and about
20% to 40% probability of developing ovarian cancer. Likewise, BRCA2 mutation car-
riers have about 60% to 85% likelihood of developing breast cancer and about 10% to
20% probability of developing ovarian cancer [39, 73]. Furthermore, men with BRCA2
mutation have approximately 6% chance of breast cancer risk while men with BRCA1
mutation have a high risk of having prostate cancer.
The breast cancer genes mentioned above are described as high penetrance in the sense
that both women and men who have mutations in them are linked with high risk of
developing breast cancer and other subtypes of cancer. Meanwhile, there are several
other genes associated in one way or the other to developing high risk of breast cancer.
Some of them are features of rare genetic syndromes including: Li-Fraumeni syndrome
often caused by p53 gene mutations; Cowden syndrome usually caused by PTEN gene
mutations; Ataxia-telangiectasia caused by homologous in the ATM gene; hereditary dif-
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Figure 4.3: Degree distribution of detected k function interactions per protein against
the connection frequency P(k).
fuse gastric cancer resulting from CDH1 gene mutations; Peutz-Jeghers syndrome which
mainly derives from STK11 gene mutations; and Muir-Torre syndrome typically results
from MSH2 gene mutations [123]. Table 4.3 lists the genes associated with breast can-
cer with their description obtained from the UniProt knowledge-base database (http:
//www.uniprot.org ).
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Table 4.3: Description of human target proteins associated with breast cancer.
UniProt-ID Gene name Description
P38398 BRCA1 Breast cancer type 1 susceptibility protein
(EC:2.3.2.27)(RING finger protein 53)
P51587 BRCA2 Breast cancer type 2 susceptibility protein (Fanconi anemia
group D1 protein)
Q8NBR0 p53 Tumor protein p53-inducible protein 13 (Damage-
stimulated cytoplasmic protein 1)
P60484 PTEN Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase
and dual-specificity protein phosphatase PTEN
(EC:3.1.3.16,EC:3.1.3.48,EC:3.1.3.67) (Mutated in multi-
ple advanced cancers 1)
Q13315 ATM Serine-protein kinase ATM (EC:2.7.11.1)(Ataxia telangiecta-
sia mutated)
P12830 CDH1 Cadherin-1(Epithelial cadherin)
Q15831 STK11 Serine/threonine-protein kinase STK11(EC:2.7.11.1) (Liver
kinase B1(LKB1))
P43246 MSH2 DNA mismatch repair protein Msh2(MutS protein ho-
molog 2)
I3L2S5 PALB2 Partner and localizer of BRCA2
Q99728 BARD1 BRCA1-associated RING domain protein 1 (EC:2.3.2.27)
(RING-type E3 ubiquitin transferase BARD1)
Q9BX63 BRIP1 Fanconi anemia group J protein (EC:3.6.4.13) (BRCA1-
interacting protein C-terminal helicase 1)
Q06609 RAD51 DNA repair protein RAD51 homolog 1
Q14790 CASP8 Caspase-8 (EC:3.4.22.61)(Apoptotic cysteine protease)
P54278 PMS2 Mismatch repair endonuclease PMS2 (DNA mismatch re-
pair protein PMS2)
O96017 CHEK2 Serine/threonine-protein kinase Chk2 (EC:2.7.11.1)
(Checkpoint kinase 2)
P16410 CTLA4 Cytotoxic T-lymphocyte-associated antigen 4
Q05D78 MRE11A MRE11A protein
P11511 CYP19A1 Aromatase (EC:1.14.14.14) (Cytochrome P450 19A1)
O60934 NBN Nibrin (Cell cycle regulatory protein p95)
P21802 FGFR2 Fibroblast growth factor receptor 2 (EC:2.7.10.1) (Ker-
atinocyte growth factor receptor)
P40692 MLH1 DNA mismatch repair protein Mlh1 (MutL protein ho-
molog 1)
P33241 LSP1 Lymphocyte-specific protein 1
Q92878 RAD50 DNA repair protein RAD50
O43502 RAD51c DNA repair protein RAD51 homolog 3
O14746 TERT Telomerase reverse transcriptase (EC:2.7.7.49)(Telomerase-
associated protein 2)
O15405 TOX3 TOX high mobility group box family member 3
O43543 XRCC2 DNA repair protein XRCC2 (X-ray repair cross-
complementing protein 2)
O43542 XRCC3 DNA repair protein XRCC3 (X-ray repair cross-
complementing protein 3)
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Mutation in PALB2, BARD1, LKB1, BRIP1, RAD51, CASP8, PMS2, CHEK2, CTLA4,
MRE11A, CYP19A1, NBN, FGFR2, MLH1, LSP1, TERT, RAD50, TOX3, XRCC2, RAD51c
and XRCC3 genes and several other genes according to research are possible risk factors
for breast cancer and are described as low penetrance because of their little contribution
to breast cancer risk. Interactions between proteins produced by these genes and the
BRCA1 or BRCA2 as been suspected by researchers to have significant impact in carrier
risk of developing breast cancer [39, 73, 123]. We shall therefore proceed in the next sec-
tion to identify proteins (breast cancer genes) that regulates key cytokines in our model.
4.3 Retrieving Potential Breast Cancer Genes
From our model results, we are able to identify five cytokines that play key roles in the
dynamics of tumor-immune interactions in the tumor microenvironment, of which are
the tumor promoting cytokines: IL-10, IL-23, and TGF-β, and tumor suppressing cy-
tokines: TNF-α and IFN-γ. We peruse several literatures to identify essential proteins
from the aforementioned breast cancer genes which somehow regulates the derived key
cytokines. According to Wang et al.(2013), the ATM pathway regulates IL-23 expression
by human dendritic cells [113], while activation of LSP1 gene results in the downregu-
lation of IL-23 production [23]. Also according to Li et al. (2016), TGF-β1 production
and the TGF-β signalling pathway are inhibited by tumor suppressive function of LKB1
in breast cancer cells [62]. Meanwhile TGF-β was stated to downregulate the expression
of PTEN [22], MSH2, ATM, BRCA1 and BRCA2 [65] in breast cancer cells. Also TGF-β
upregulates CTLA4 [127], while TGF-β-SNAI 2 signalling was reported by Ding et al.
(2013) to suppress CDH1 [30]. The subsets of TGF-β target genes are differentially reg-
ulated by p53 thereby promoting cancer malignancy [51]. Gene p53 directly regulates
IL-10 localization [85] while IL-10 mediate the regulation of CASP8 activation [43].
For the case of the tumor suppressing cytokines IFN-γ, tumor suppressor gene BRCA1
regulates the IFN-γ-mediated apoptotic response [3], while the expression of IFN-γ re-
lated genes are regulated by BRCA2 [118]. LKB1 which is a central regulator of T cell
development, activation and metabolism was reported to elevate IFN-γ production [68].
Also, data from Leong et al.(2015) suggested that PTEN might promote IFN-γ produc-
tion [61] while dos Santos and Isabel (2012) in their work, identified ATM as a regulator
of IFN-γ response [32]. According to Ruiz-Ruiz et al. (2004), CASP8 expression are
elevated when human breast cancer cells are being treated with IFN-γ [92], while IFN-
γ/Interferon regulatory factor-1(IRF-1)-induced p27kip1 down-regulates human telom-
erase reverse transcriptase(hTERT) expression and telomerase activity in human cervical
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cancer [59].
Lastly, breast cancer genes such as PTEN, CASP8 and p53 regulate the tumor sup-
pressing cytokines TNF-α [42, 84, 106] with ATM being a key regulator of TNF-α acti-
vated ERK/p38 NF-kappaB pathway[119], while an LKB1 interacting protein negatively
regulates TNF-α induced NF-kappaB activation[66]. Moreover, TNF-α serves as a regu-
lator for both BRCA1 and BRCA2 expression [11] and downregulates CDH1[121]. Hence,
from all the human genes associated with breast cancer that were retrieved as previously
elucidated, only those identified to be target genes and are able to regulate our model
key cytokines are summarized in Table 4.4 with key cytokines they triggered. We then
proceed by mapping these target genes identified onto the unified functional network
in order to select those which are key proteins.
Table 4.4: Human target proteins associated with breast cancer with cytokines they trig-
ger.
Gene name Cytokines
PTEN TNF-α, TGB-β, IFN-γ
BRCA1 TNF-α, TGB-β, IFN-γ
ATM IL-23, TNF-α, TGB-β, IFN-γ
CDH1 TNF-α, TGB-β
CASP8 IL-10, TNF-α, IFN-γ
MSH2 TGB-β
TERT IFN-γ
CTLA4 IL-10, TGB-β, IFN-γ
BRCA2 TNF-α, TGB-β, IFN-γ
LSP1 IL-23
p53 IL-10, TNF-α, TGB-β
LKB1 TNF-α, TGB-β, IFN-γ
4.4 Selecting Essential Breast Cancer Genes
In this section, we identify and elucidate clusters containing key target proteins within
the unified functional network. We employ clustering method used by Blondel et al.,
which has been proven to outperform other methods used in clustering different func-
tional networks [10]. A total of 90 clusters were generated from the unified human
protein functional network with the biggest cluster containing 4169 proteins. We iden-
tified 858 key proteins in the unified human functional network using the degree and
closeness with the degree and betweenness joint threshold values. These threshold val-
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ues are approximate as follows, 215 for degree measure, 1/2.631 ≈ 0.38 for closeness
measure as defined in (2.4.2) and 51310.54 for the betweenness measure.
Table 4.5: Distribution of human proteins and key proteins in 5 different clusters in
terms of number of proteins (#pr), key proteins (#KPr), target proteins (TPr) and key
target proteins (KTPr).
Cluster ID #Pr #KPr TPr KTPr
0 3857 140 p53 Nil
2 4619 299 CDH1, PTEN, TERT,
CASP8, and CTLA4
CDH1, PTEN, TERT,
and CASP8
3 2783 164 ATM, BRCA1, and
BRCA2
ATM and BRCA1
7 1274 135 MSH2 MSH2
8 1200 120 LSP1 Nil
Total 13 733 858 11 7
Among the 90 clusters in the unified human functional network, only 11 clusters
contains key proteins of which the target proteins are distributed among only 5 clusters
as shown in Table 4.5, with 299 key proteins in the biggest cluster. Hence, analysing
the target proteins at the system level using the unified human functional network, out
of the previously listed target proteins, we identified 7 key target proteins associated
with breast cancer, and are given in Table 4.6 with their respective network centrality
scores. These human key target proteins are contained in three of the five clusters con-
taining human target proteins, as previously elucidated. They are therefore considered
to be breast cancer target proteins and promising target for further research towards the
development of new drug and vaccine for breast cancer.
Table 4.6: Human key target proteins associated with breast cancer with their network
centrality scores.
Gene name Betweenness Closeness Degree
PTEN 149261.55 0.47858 1047
BRCA1 207445.38 0.47151 1159
ATM 106979.92 0.46922 906
CDH1 235111.26 0.46682 817
CASP8 70405.12 0.45799 550
MSH2 58147.12 0.45653 676
TERT 216312.77 0.45582 439
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Furthermore, we perform enrichment and pathway analysis to identify enriched bio-
logical processes and pathways in which the human proteins interacting with the breast
cancer-associated key proteins are involved. In order to do this, we considered the clus-
ter containing high penetrance genes, BRCA1 and BRCA2 (cluster #3) as a breast cancer
genetic cluster with a total number of 2783 human proteins. Hence we performed func-
tional analysis on this genetic cluster in the next sections.
4.5 Process and Pathway Enrichment Analysis
To gain insight into the enriched biological processes in which a set of the target protein
is involved, we performed process and pathway enrichment analysis using the follow-
ing annotation databases: Gene Ontology (GO) [24], Gene Ontology Annotation (GOA)
[14] and Kyoto Encyclopedia of Genes and Genomes (KEGG) [82]. For the process anal-
ysis, GO and the GOA mapping given by the UniProtKB-GOA dataset was used [74, 78].
It contains evidence-based annotations and biological description of individual proteins.
The domains of GO include biological processes, molecular function or cellular compo-
nent [24]. In the course of this study, we only focused on predicting enriched biological
processes of the target proteins. For the pathway enrichment analysis, we used KEGG
data sets extracted from the KEGG database at (http://www.genome.jp/kegg/). KEGG
pathway, in this study, is used to map key proteins in the genetic cluster with biological
functional information or interacting molecules in cells.
Process and pathway enrichment analysis use different statistical methods to deter-
mine the enriched biological process and significant pathway associated with the out-
come of a disease [33]. They are Fisher’s exact, hypergeometric and χ2 test. In this study,
we used a hypergeometric distribution test, because it appropriately models the proba-
bility that a particular annotation term occurs j times in the list of target proteins. The
p-value for each process or pathway is the probability of observations made on at least
x proteins involved in the process or pathway under consideration and it is calculated
using its frequency in the dataset [74, 77]. The formula is given by
P[X ≥ x] = 1−
x−1
∑
k=0
(
m
k
)(
N −m
n− k
)
(
N
n
) .
where the random variable X is the number of occurrences of the target-associated
process or pathway within a given target gene set of size n, knowing that the refer-
ence dataset (whole human proteome) contains m such annotated genes out of N genes
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[74, 77]. The p-value obtained was adjusted using the Bonferroni multiple testing cor-
rection, and we selected GO terms and pathway enriched in our target proteins list by
requiring a p-value less than 0.05 [78].
In the following section, a detailed discussion on the identified GO terms and KEGG
pathways will be presented.
4.5.1 Enriched biological processes associated with breast cancer
The main GO terms associated with the target protein list in the genetic cluster were
identified as a result of performing statistically enriched biological processes on key
proteins in the breast cancer genetic cluster. A total of 15 biological processes were
found to be significant for breast cancer disease outcome in human (see Table 4.7). The
higher the level, the more specific the GO term.
Among the enriched biological processes of human proteins predicted to interact
with associated breast cancer proteins, are the activation of different levels of Mitogen-
activated protein kinases (MAPKs). They include GO:0000185 (activation of MAPKKK
activity), GO:0000187 (activation of MAPK activity) and GO:0000186(activation of MAPKK
activity).
Table 4.7: 15 most statistically significant GO biological process terms associated with
target proteins in the BRCA genetic cluster.
GO-ID Biological Process Level p-value Adjusted p-value
GO:0000185 activation of MAPKKK activity 13 1.68× 10−5 0.01244
GO:0000187 activation of MAPK activity 13 5.08× 10−6 0.00376
GO:0000186 activation of MAPKK activity 13 1.68× 10−5 0.01244
GO:0007254 JNK cascade 11 4.28× 10−5 0.03166
GO:0000086 G2/M transition of mitotic cell cycle 7 2.05× 10−6 0.00152
GO:0006977 DNA damage response, signal transduction by p53
class mediator resulting in cell cycle arrest
13 8.24× 10−7 0.00061
GO:0010768 negative regulation of transcription from RNA poly-
merase II promoter in response to UV-induced DNA
damage
13 5.76× 10−5 0.04262
GO:0007179 transforming growth factor beta receptor signaling
pathway
8 1.70× 10−5 0.01261
GO:0008543 fibroblast growth factor receptor signaling pathway 8 4.73× 10−6 0.00349
GO:0060070 canonical Wnt signaling pathway 8 1.54× 10−5 0.01141
GO:0002755 MyD88-dependent toll-like receptor signaling path-
way
12 6.02× 10−6 0.00446
GO:0002223 stimulatory C-type lectin receptor signaling pathway 11 2.41× 10−5 0.01783
GO:0006879 cellular iron ion homeostasis 10 1.66× 10−6 0.00123
GO:0070987 error-free translesion synthesis 10 3.34× 10−5 0.02473
GO:0035635 entry of bacterium into host cell 8 6.02× 10−6 0.00446
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Four classes of MAPK intracellular signalling cascade are involved in breast disease
and operate in mammary epithelial cells. They include the extracellular regulated ki-
nases (ERK) 1/2 pathway, the ERK5 pathway, the p38 pathway and the c-Jun N-terminal
kinases (JNK pathway) [52, 58]. As indicated in Table 4.7, JNK pathway (GO:0007254)
is an essential biological process associated with breast cancer. Furthermore, p38 MAP
kinase has been shown to be implicated in complex biological processes including cell
differentiation, proliferation, migration, invasion, apoptosis, and responses to environ-
mental stress [58]. Dysregulation of p38 MAPK levels in cancer patient results in ad-
vanced stages and short survival of the patient [58]. Moreover, dysregulated ERK1/2
signalling alone is insufficient to cause cancer. However, additional crosstalk with other
major signaling networks such as p53 and PTEN, enhances cell proliferation, prevents
apoptosis and sometimes induces drug resistance [52]. Yue et al. (2002) reported that
MAPK activation also enhances long-term estrogen deprived MCR-7 human breast can-
cer cells to cause hypersensitivity to the mitogenic effect of estradiol (E(2)) [124].
Enriched biological process GO:0000086 (G2/M transition of mitotic cell cycle) deals
with the process of cell division of the mother cell into two daughter cells genetically
identical to each other. BRCA1 is known to be required for S and G2/M transition which
are involved in the cellular response to DNA damage [111]. Also, they help prevent
damaged DNA from entering mitosis due to trigger from ATR (Ataxia Telangiectasia
and Rad3-related) and Chk1 (Checkpoint kinase 1) [112]. GO:0006977 (DNA damage
response, signal transduction by p53 class mediator resulting in cell cycle arrest), in
agreement with DNA damage, can cause cell cycle arrest (i.e. when cell has entered a
quiescent stage and no longer active in the process of cell division) through induction
of the p53 pathway (tumor suppressor) which can lead to initiation of DNA repair of
apoptosis [126].
Another enriched biological process, GO:0010768, is related to the negative regu-
lation of transcription from RNA polymerase II promoter in response to UV-induced
DNA damage. This is in agreement with the fact that large subunit of RNA polymerase
II is ubiquitinated in cells after UV-irradiation treatment which include DNA damage
preferentially repaired transcriptional-coupled repair (TCR). Moreover, specific muta-
tion in genes is known to cause a defect in TCR including BRCA1, which is defective
in TCR of oxidative DNA damage [44]. Various pathways such as: GO:0007179 (trans-
forming growth factor beta (TGF-β) receptor signaling pathway), GO:0008543 (fibroblast
growth factor receptor (FGFR) signaling pathway), GO:0060070 (canonical Wnt signal-
ing pathway), and GO:0002755 (MyD88 (myeloid differentiation primary response gene
88)-dependent toll-like receptor signaling pathway) have been predicted to be identi-
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fied in breast cancer. Concerning TGF-β receptor signaling pathway, TGF-β has a dual
effect on tumor growth, in the sense that, it switches its role from suppressor of primary
tumor initiation to a promoter of the later malignant stages. Improved prognostic in-
formation for breast cancer patient might be obtained by assessing interaction among
TGF-β signaling biomarkers [25].
Likewise, FGFR signaling is implicated in biological processes, such as cell differen-
tiation, proliferation, survival, migration, and apoptosis. Alteration in these processes
can promote the development and progression of a tumor. Due to its role in the activa-
tion of critical signaling pathways and contribution towards the pathogenesis in breast
cancer, targeting FGFR has been highlighted to provide a new opportunity for breast
cancer therapeutic strategies [114]. Canonical Wnt signaling dysfunction, on the other
hand, mediates the progression of triple-negative breast cancer [88]. As for MyD88-
dependent signaling, it was revealed that it enhances the expression of genes that could
promote breast cancer progression and have the ability to suppress the expression of
genes capable of inhibiting breast cancer progression [49].
Another enriched biological process identified is GO:0002223 (stimulatory C-type
lectin receptor signaling pathway). C-type lectin receptors (CLRs) are primarily ex-
pressed on myeloid cells (macrophages and dendritic cells). Similar to Toll-like re-
ceptors, CLRs signaling are implicated in different levels of innate immune response
initiation and promote the production of soluble factors such as cytokines and interfer-
ons [95]. Also, intracellular routing of antigen through CLR enhances the presentation
of antigen through MHC class I and II molecules. It thereby induces antigen-specific
CD4+ and CD8+ T cell proliferation [103]. Agonist or antagonist of CLRs signaling has
been therefore suggested to be a potential therapeutic reagent for cancer immunother-
apy [95, 103].
GO:0006879 (cellular iron ion homeostasis) involves upkeep of an internal steady
state of iron ions at a cell’s level. Several studies have linked iron to carcinogenesis,
either by continuous failure in the redox balance or due to its vital role in cellular prolif-
eration. Alteration in the processes cellular iron has been reported to likely contribute to
breast cancer behavior, development, and recurrence [72]. Also, GO:0070987 (error-free
translesion synthesis) involves DNA polymerase that promotes DNA replication by ef-
ficiently neglecting different DNA lesions in a relatively error-free manner [70]. Studies
postulated that the increased number of translesion synthesis polymerases developed
gradually in a higher organism as a tumor suppressive adaptation [55]. Lastly, the tar-
get proteins are also enriched in biological process GO:0035635 (entry of bacterium into
host cell), in which recent researches have shown interesting results suggesting the ef-
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fectiveness of bacteria as an agent for cancer treatment [101].
We shall proceed to briefly highlight the identified enriched pathway in the next
section.
4.5.2 Enriched pathways associated with breast cancer
We identified 21 enriched KEGG pathways (see Table 4.8) in which target proteins in
the genetic cluster are implicated. According to several published literature, all of these
pathways identified in this study have been confirmed to participate in breast cancer
associated biological processes. As we have mentioned earlier, pathways such as Wnt
signaling pathway, TGF - β signaling pathway and p53 signaling pathway have been
reported to contribute to the growth and progression of human breast cancer. Among
other KEGG pathways identified is pathways in cancer. This pathway describes the
kernel regulatory factors that contribute to the initiation and progression of pan-cancer
[122]. Another subtype of cancer, renal cell carcinoma associated biological process,
have also been predicted to be associated with breast cancer [109].
Another enriched pathway identified, Hypoxia-inducible factor 1(HIF-1) signaling
pathway, is a transcription factor that acts as a major regulator of oxygen homeostasis
within cells. Gilkes and Semenza (2013) reported that breast cancer patients with high
HIF expression levels in primary tumor biopsies are at risk of angiogenesis, metastasis,
and resistance to apoptosis. In addition to intratumoral hypoxia, alteration in EGFR
(Epidermal growth factor receptor), PTEN, Tp53 and HER2 (human epidermal growth
factor receptor 2) signaling pathways also regulate the expression of HIF-dependent of
target genes [40]. As for RIG-I- like receptor (RLR) signaling pathway, activation of RLR
causes immunogenic cell death of virus-infected cells which is followed by increased
production of inflammatory cytokine and antigen presentation. In recent studies, a dif-
ferent approach to non-infectious RIG-I activation in cancer is being investigated as a
treatment option, with a potentially high cytotoxic function of tumor-infiltrating lym-
phocytes [35].
Concerning the KEGG pathway MicroRNAs (miRNAs) in cancer, dysregulated miR-
NAs have been shown to play a crucial role in almost all cancer subtypes including
breast cancer [20]. Altered expression of miRNA in breast cancer cell lines is linked
with altered cell cycle progression and cell proliferation. Several analyses carried out
on miRNA expression suggested oncogenic or tumor suppressive roles of miRNAs [60].
Moreover, KEGG pathway hsa04330 which describes the Notch signaling pathway has
been predicted to contribute to breast cancer. As a regulatory mechanism for cell prolif-
eration, differentiation, and survival, increased Notch signaling has agreed with therapy
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Table 4.8: Enriched KEGG pathways associated with target proteins in the BRCA genetic
cluster.
Pathway-ID Pathway-Name p-value Adjusted p-value
hsa04310 Wnt signaling pathway 1.31× 10−8 1.99× 10−6
hsa04350 TGF - beta signaling pathway 5.64× 10−7 8.57× 10−5
hsa04115 p53 signaling pathway 4.36× 10−5 0.00662
hsa05200 Pathways in cancer 1.62× 10−4 0.02463
hsa05211 Renal cell carcinoma 1.65× 10−4 0.02502
hsa04066 HIF - 1 signaling pathway 7.80× 10−5 0.01216
hsa04622 RIG - I - like receptor signaling pathway 3.55× 10−6 0.00054
hsa05206 MicroRNAs in cancer 4.42× 10−5 0.00672
hsa04110 Cell cycle 1.57× 10−5 0.00238
hsa04330 Notch signaling pathway 5.24× 10−6 0.00079
hsa04120 Ubiquitin mediated proteolysis 5.87× 10−9 8.93× 10−7
hsa04520 Adherens junction 1.65× 10−4 0.02502
hsa04114 Oocyte meiosis 2.04× 10−4 0.03106
hsa04710 Circadian rhythm 1.49× 10−7 2.27× 10−5
hsa04530 Tight junction 1.32× 10−5 0.00200
hsa05165 Human papillomavirus infection 3.79× 10−5 0.00577
hsa05162 Measles 3.44× 10−7 5.23× 10−5
hsa05169 Epstein - Barr virus infection 1.39× 10−5 0.00211
hsa05016 Huntington’s disease 3.27× 10−4 0.04965
hsa05166 HTLV - I infection 3.73× 10−5 0.00566
hsa05164 Influenza A 1.16× 10−7 1.77× 10−5
resistance in oestrogen receptor-positive breast cancer. Recent analysis shows the impor-
tance of Notch signaling in BRCA progression via triggering epithelial-mesenchymal
transition (EMT) [83].
Furthermore, for enriched KEGG pathway Ubiquitin-mediated proteolysis, protein
ubiquitination occurs through sequential activation and conjugation of ubiquitin to tar-
get proteins by a reaction cascade consisting of three enzymes namely: the ubiquitin-
activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3)
[64]. Several studies have indicated that many E3s in breast cancer function as either
oncogenes or tumor suppressor genes. Also, most cancers related E3s regulate the cell
cycle, p53, transcription, DNA repair, cell signaling, and apoptosis [21]. Among other
enriched pathways identified, adherens junction is crucial for maintaining tissue archi-
tecture, cell polarity and can reduce cell movement and proliferation. Tumor suppres-
sor gene E-cadherin (CDH1) serves as an essential cell adhesion molecule, and any loss
of E-cadherin mediated adhesion form the transition from benign lesions to invasive,
metastatic cancer. Also, evidence shows that E-cadherin may also play a role in the Wnt
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signal transduction pathway [87].
Other results from our KEGG pathway analysis also showed that, pathogenesis of
breast cancer is associated with other biological processes such as Oocyte meiosis [117],
Circadian rhythm [9] and Tight junction [12]. We also identified several disease-enriched
pathways associated with breast cancer. They include: Human papilloma virus infection
[5], Measles [5], Epstein-Barr virus infection [5], Huntington’s disease [102], human T-
lymphotropic virus type 1(HTLV-I) infection [96] and Influenza A [48]. Infection of such
viruses has been confirmed to increase risk of breast cancer.
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In this study, we developed a new mathematical model describing the dynamics of tu-
mor growth and the host immune system components in the tumor microenvironment.
These components include: resting macrophages, M1 macrophages, M2 macrophages,
natural killer (NK) cells, dendritic cells (DCs), helper T cells (CD4+ T cells) and its sub-
sets, effector T cells (CD8+ T cells), tumor cells, pro-inflammatory cytokines (IL-2, IL-12,
IL-17, IL-21, TNF-α, and IFN-γ) and anti-inflammatory cytokines (IL-4, IL-5, IL-6, IL-4,
IL-10, IL-13, IL-23, and TGF-β). In addition to this, the local and global stability of the
tumor-free equilibrium point was established. We found that tumor free equilibrium
will be globally asymptotically stable if the elimination rate of M2 macrophages by Th1
cells is more than the transition of M1 macrophages to M2 macrophages caused by both
Th2 cells and tumor cells. Sensitivity analysis on estimated parameters was done to
show the parameters that play an important role in the dynamics of the tumor.
From the simulation of our model, we predicted that few cytotoxic immune cells
(i.e., NK cells and CD8+ T cells) at the tumor site lead to tumor escape from the mech-
anisms of immunological surveillance (see Figure 3.3). Our model, therefore, supports
strengthening the cytotoxic immune cells in the tumor microenvironment which we see
as a significant way of contributing to tumor regression (see Figure 3.6). Also, from the
analysis of our model, cytokines, such as IL-10, IL-23, TNF-α, TGB-β, and IFN-γ, have
been shown to contribute significantly to the dynamics of tumor growth based on the
observed dynamics in the level of concentrations in the tumor microenvironment (see
Figure 3.9 and 3.10).
In particular, IL-23 concentration compared to others was observed to be strong at
the tumor site contributing to termination of the innate immune cells activities. It in-
duces immuno-suppression through down-regulation of CD4+ and CD8+ T cells infil-
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trating in tumor tissues as reported in previous research thereby leading to tumor pro-
gression. It was further observed that the depletion of the tumor suppressing cytokines
lead to a decrease in the population, efficiency and cytotoxic effect of the immune ef-
fector cells while when there are high cytotoxic immune cells at tumor site, IL-23 con-
centration was observed to be minimal in the tumor microenvironment leading to the
elimination of the tumor cells. This supports the idea from previous research that tu-
mor promoting cytokine IL-23 plays a significant role in the growth and proliferation of
tumor and its antibody can, therefore, be used to achieve an increased tumor eradica-
tion or a delayed tumor growth. All these cytokines are therefore considered to be key
cytokines and were used for further analysis in this research.
Finally, switching of an immune (effector) cell from resting to active states, is trig-
gered by some proteins working in a complex protein-protein interaction (PPI) network.
We presented a unified human functional protein-protein interaction network using hu-
man protein sequences database gotten from different biological data sources. We used
text mining technique to identify proteins (breast cancer genes) that regulate key cy-
tokines in our model. Furthermore, with the aid of network centrality measures, we
identified proteins which are essential to the functioning of the system. We proceeded
by classifying essential proteins in human functional networks and elucidated clusters
containing key target proteins in the network. We considered the cluster containing high
penetrance genes, BRCA1 and BRCA2, as a breast cancer genetic cluster and performed
functional analysis on this genetic cluster.
For the process analysis, GO and GOA mapping given by the UniProtKB-GOA dataset
were used while for the enrichment pathway analysis, KEGG data sets extracted from
the KEGG database at (http://www.genome.jp/kegg/) were considered. A hypergeo-
metric test was employed to predict enriched biological processes and significant path-
ways of target proteins associated with breast cancer. From the results of the analysis,
a total of 15 biological processes and 21 enriched KEGG pathways were found to be
essential for breast cancer disease outcome. Most of the enriched processes and path-
ways are related to the immune system signaling pathways, thereby enabling the host
to detect the cancer cells and respond. We also observed several disease-enriched path-
ways including Human papillomavirus infection, Measles, Epstein-Barr virus infection,
Huntington’s disease, human T-lymphotropic virus type 1(HTLV-I) infection and In-
fluenza A are associated with breast cancer. These biological processes, pathways and
essential proteins identified can, therefore, be further assessed to check for their suitabil-
ity as targets for the breast cancer disease for the development of effective therapeutic
strategies.
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